



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 239/96, 403/04, 471/06, 471/04, A61K 31/505	A1	(11) International Publication Number: WO 99/21840 (43) International Publication Date: 6 May 1999 (06.05.99)
(21) International Application Number: PCT/US98/19877 (22) International Filing Date: 23 September 1998 (23.09.98) (30) Priority Data: 60/063,556 28 October 1997 (28.10.97) US 60/098,588 31 August 1998 (31.08.98) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DOMAGALA, John, Michael [US/US]; 47693 Red Run, Canton, MI 48187 (US). ELLSWORTH, Edmund, Lee [US/US]; 6899 Kestrel Court, Brighton, MI 48116 (US). HUANG, Liren [CA/CA]; Apart- ment 2, 10623-68th Avenue, Edmonton, Alberta T6H 2B3 (CA). RENAULT, Thomas, Eric [US/US]; Apartment 214, 900 Pepper Tree Lane, Santa Clara, CA 95051 (US). SINGH, Rajeshwar [CA/CA]; 7927 22nd Avenue, Edmonton, Al- berta T6K 1Z2 (CA). STIER, Michael, Andrew [US/US]; 4886 Club Place, Ypsilanti, MI 48197 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS		
(57) Abstract The invention is a series of 7-substituted quinazolin-2,4-diones useful as antibacterial agents, processes for the preparation of the compounds, and a pharmaceutical composition containing one or more of the compounds.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						


-1-

NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS
ANTIBACTERIAL AGENTS

BACKGROUND OF THE INVENTION


Antibiotic resistance is a worldwide problem (*J. Med. Chem.*,
1996;39:3853) with catastrophic potential (*Southern Med. J.*, 1995;88:797). In
1995, the American Society of Microbiology Task Force issued a report defining
the resistance problem and calling for new antibacterial agents with novel
structures or mechanisms to offer alternatives to existing therapeutic choices.

The quinolone antibacterials as exemplified by ciprofloxacin **1** represent a
significant addition to the therapeutic options currently available. The quinolones
are potent, inhibit gram positive and gram negative bacteria, and may be
administered orally or IV. The quinolones also have several significant side effects
(*J. Antimicrob. Chemother.*, 1994;33:685), and significant resistance has been
frequently noted (Gootz, Medicinal Research, 1996;Rev. 16:433).




The quinolones have a distinct structure activity relationship which has
been defined by several thousands of analogs prepared over the last 30 years
(Progress in Drug Research, Editor S. Mitsuhashi, 1992;38:11-147). In the
quinolone SAR, it is well-established that the N₁ group with the C₃-carboxyl and
the C₄ carbonyl are essential for activity and that any substituents at C₂ detract
from activity (*J. Antimicrob. Chemother.*, 1994;33:685 and Gootz, *supra.*, 1996). It
is also well-established that R₆ is ideally fluorine, and that R₇ is a nitrogen
containing heterocycle. R₁ is ideally a small alkyl, cycloalkyl, or a phenyl group.

-2-




The quinolones inhibit bacterial growth by inhibition of DNA gyrase and Topoisomerase IV (Gootz, *supra.*, 1996). The gyrase interaction appears to rely on the N₁-C₄-carbonyl-C₃-carboxyl relationship.

Attempts to design novel quinolone mimics have focused on the N₁-C₄-carbonyl-C₃-carboxyl relationship. Compounds of type **3** were designed to keep an all planar relationship and to have the NH of the isothiazole ring be as acidic as the quinolone CO₂H (*Chu, Drugs Exptl. Clin. Res.*, 1990;16:215). While maintaining excellent quinolone activity, these compounds also showed antitumor and mammalian topoisomerase activity (*Drugs of the Future*, 1992;17:1101) which is undesired in an antibacterial agent.



Several publications (U.S. Patent No. 5,283,248; *J. Med. Chem.*, 1992;35:1358; *Antimicrob. Agents Chemother.*, 1995;39:163) cite compounds of type **4** as having antibacterial activity and inhibition of DNA gyrase. In compounds **4**, the relationship of the N₁ to the C₄ carbonyl has been skewed. Compounds of type **4** were also ineffective against bacteria that were quinolone resistant.




-3-




Compounds of type **5** have also been revealed as quinolone mimics (JP 4,091,090 3/92; Interscience Conference on Antimicrobial Agents and Chemotherapy 1991, Abstract 1494). These agents were reported to possess antibacterial and gyrase activity. While the ideal N₁-C₄-carbonyl relationship is maintained in **5**, the C₂ region where substitution is undesirable in the quinolones is filled with a major part of the ring. None of the quinolone mimics **3-5** exactly mimics the quinolone parent structure because all contain an extra third ring used to deliver the acidic H group required for activity.

WO 96/04288 describes a series of benzoheterocycles **6** which are glycine receptor antagonists. X, Y, and Z are chosen to provide hydrogen bond acceptor and donator groups. Among the compounds depicted are some N-hydroxy-quinazoline-2,4-diones **7**, where R₁-R₄ may be hydroxy, amino, nitro, a variety of alkyls, esters, and amides. In all cases, the substituent on N₁ is hydrogen. None of the substituents R₁-R₄ are nitrogen containing heterocycles. No antibacterial activity is revealed.

-4-




United States Patent No. 5,155,110 (10/92) reveals certain N₁-aryl-N-hydroxy-quinazoline-2,4-diones **8** as cyclooxygenase and lipoxygenase inhibitors. R may be halo, cyano, hydroxy, alkoxy, and substituted amino. Amino
 5 heterocycles are not included in R, and no antibacterial activity is described.



SUMMARY OF THE INVENTION

Described are compounds of Formula I which are new:



-5-

or a pharmaceutically acceptable salt thereof wherein:

R₁ is H, a straight or branched alkyl of 1 to 6 carbons, cycloalkyl of 3 to 6 carbons, a heterocycle of 4 to 6 atoms having 1 to 2 heteroatoms, or a phenyl group, each is optionally substituted by R, F, Cl, OR, or N(R)₂ wherein R is H, a
5 straight or branched alkyl of 1 to 6 atoms having 0 to 1 degrees of unsaturation, a ring of 3 to 6 atoms having 0 to 2 heteroatoms, or a phenyl group, each may be substituted by F, Cl, CN, NO₂, OH, NH₂; also, two R's may form a 3- to 7-membered ring with the atom to which it is attached which ring may have 0 to 1 heteroatoms;

10 R₅, R₆, and R₈ are each independently H, F, Cl, Br, NO₂, CN, CF₃, (C(R)₂)_nOR, (C(R)₂)_nCO₂R, (C(R)₂)_nCON(R)₂, (C(R)₂)_nN(R)₂, (C(R)₂)_nNRCOR, a straight or branched alkyl of 1 to 4 carbons containing 0 to 1 degrees of unsaturation, a cycloalkyl of 3 to 6 carbons, each optionally substituted by F, Cl, OR, or N(R)₂ wherein R is as defined above;

15 R₁ and R₈ may form a ring of 6 to 7 atoms having 1 to 2 heteroatoms which ring may be substituted by one or more R's wherein R is as defined above;

R₇ is selected from R₅, R₆, R₈, a carbocycle of 3 to 7 carbons, a phenyl, or a heterocyclic ring of 4 to 7 atoms, a fused heterocyclic ring of 8 to 10 atoms, a bicyclic heterocycle of 6 to 9 atoms, or a spiro heterocycle of 7 to 12 atoms each
20 having 1 to 4 heteroatoms, and each of which is optionally substituted by one or more of R', F, Cl, (C(R)₂)_nN(R)₂, (C(R)₂)_nOR, O, (C(R)₂)_nCON(R)₂, (C(R)₂)_nCOR, (C(R)₂)_nNRCOR, (C(R)₂)_nCO₂R, wherein R is defined above and R' is defined as R which is defined above; any of the adjacent groups R₅-R₈ may together form a 5- to 7-membered ring having 0 to 2 heteroatoms, which
25 rings may be substituted by any of the groups described for R₇;

n is an integer of from 0 to 3; and

X and Y are each independently carbon or nitrogen with the understanding that if X or Y is nitrogen, no substituent R₆ or R₈ is attached.

-6-

The invention is also a pharmaceutical composition of the above compounds and methods of using the compounds as pharmaceuticals useful in the treatment of bacterial infection.

DETAILED DESCRIPTION

5 Preferred compounds of the invention are those of Formula I in which:

R_1 is methyl, ethyl, cyclopropyl, *t*-butyl, 2-fluorocyclopropyl, 1- or 2-methylcyclopropyl, cyclopropylmethyl, $CHCH_2$, 4-fluorophenyl, or 2,4-difluorophenyl;

10 R is H, a straight or branched alkyl of 1 to 6 atoms, a ring of 3 to 6 atoms having 0 to 2 heteroatoms, or a phenyl group, each may be substituted by F, Cl, OH, NH_2 ; alternatively two R 's may form a 3- to 7-membered ring having 0 to 2 additional heteroatoms;

15 R_5 , R_6 , and R_8 are each independently H, F, Cl, Br, NO_2 , CN, CF_3 , $CH=CH_2$, $(C(R)_2)_nOR$, $(C(R)_2)_nCO_2R$, $(C(R)_2)_nCON(R)_2$, $(C(R)_2)_nN(R)_2$, $(C(R)_2)_nNRCOR$, a straight or branched alkyl of 1 to 4 carbons, a cycloalkyl of 3 to 6 carbons wherein the alkyl or cycloalkyl is optionally substituted by F, Cl, OR, or $N(R)_2$;

20 R_7 is selected from R_5 , R_6 , R_8 , a heterocyclic ring of 4 to 7 atoms, a fused heterocyclic ring of 8 to 10 atoms or a bicyclic heterocycle of 6 to 9 atoms, each having 1 to 4 heteroatoms, and each of which may be substituted by one or more of R' , F, Cl, $(C(R)_2)_nNR_2$, $(C(R)_2)_nOR$, O, $(C(R)_2)_nCONR_2$, $(C(R)_2)_nCOR$, $(C(R)_2)_nNRCOR$, $(C(R)_2)_nCO_2R$, wherein R' is H, a straight or branched alkyl of 1 to 6 atoms having 0 to 1 degrees of unsaturation, a ring of 3 to 6 atoms having 0 to 2 heteroatoms, or a phenyl group, each may be substituted by 25 F, Cl, CN, NO_2 , OH, NH_2 ; also, two R' 's may form a 3- to 7-membered ring with the atom to which it is attached which ring may have 0 to 1 heteroatoms;

n is an integer from 0 to 3; and

X and Y are each independently carbon or nitrogen.

-7-

Other preferred compounds of the invention are those of Formula I wherein any of the adjacent groups R₅-R₈ may together form a 5- to 7-membered ring having 0 to 2 heteroatoms and such rings may be substituted by any of the groups described for R₇;

5 n is 0 to 3;

R is H, a straight or branched alkyl of 1 to 4 carbons, a ring of 3 to 6 atoms having 0 to 2 heteroatoms or a phenyl, each may be optionally substituted by F, Cl, OH, CN, NO₂, or NH₂; and

X and Y are independently carbon or nitrogen.

10 More preferred compounds of the invention are those of Formula I in which:

R₁ is ethyl, cyclopropyl, 2-fluorocyclopropyl, cyclopropylmethyl, *t*-butyl, or phenyl optionally substituted by F, Cl, OR, or N(R)₂;

R is H, methyl, ethyl, isopropyl, *t*-butyl, or phenyl;

15 R' is methyl, ethyl, phenyl, or a 2, 3, or 4-pyridyl each of which may be substituted with F, Cl, CH₃, (CH₂)_nN(R)₂, or OR;

R₅, R₆, and R₈ are each independently selected from H, F, Cl, Br, CH₃, NH₂, CH=CH₂, NO₂, and OCH₃;

20 R₇ is selected from R₅, R₆, R₈, a heterocyclic ring of 4 to 7 atoms, a fused heterocyclic ring of 8 to 10 atoms or a bicyclic heterocycle of 6 to 9 atoms, each having 1 to 4 heteroatoms, and each of which may be substituted by one or more of R', F, Cl, (C(R)₂)_nNR₂, (C(R)₂)_nOR, O, (C(R)₂)_nCON(R)₂, (C(R)₂)_nCOR, (C(R)₂)_nNRCOR, (C(R)₂)_nCO₂R, a straight or branched alkyl of 1 to 4 atoms, or a phenyl group which may also be substituted as described above;

25 n is an integer from 0 to 3; and

X is a carbon or nitrogen and Y is a carbon.

Still more preferred compounds of the invention are those of Formula I in which:

30 R₁ is ethyl, cyclopropyl, *t*-butyl, or phenyl, optionally substituted by F, Cl, OR, or NR₂;

-8-

R₅, R₆, and R₈ are each independently selected from H, F, Cl, Br, CH₃, NH₂, NO₂, and OCH₃;

R₇ is a 5- or 6-membered ring heterocycle, having 1 to 2 heteroatoms, optionally substituted by (C(R)₂)_nN(R)₂; a [4.3.0]-bridged heterocycle with 1 to 2 heteroatoms, optionally substituted by (C(R)₂)_nN(R)₂; a [3.1.0]-bridged heterocycle having 1 heteroatom, optionally substituted by (C(R)₂)_nN(R)₂; a bridged heterocycle of 7 to 9 atoms having 1 to 3 heteroatoms, or a spiro heterocycle of 7 to 12 atoms having 1 to 2 heteroatoms optionally substituted by (C(R)₂)_nN(R)₂, which heterocycles may also be substituted by R', F, Cl, or OH;

n is an integer from 0 to 3;

R is H, a straight or branched alkyl of 1 to 6 atoms, which may be substituted by F, Cl, OH, NH₂; alternatively two R's may form a 3- to 7-membered ring having 0 to 2 additional heteroatoms;

R' is a straight or branched alkyl of 1 to 4 carbons, a phenyl or a heterocycle of 5 or 6 atoms with 1 or 2 heteroatoms optionally substituted by F, Cl, OH, CN, NO₂, or (CH₂)_nN(R)₂; also, two R's may form a cyclopropyl or a cyclobutyl ring; and

X is carbon or nitrogen; and

Y is carbon.

Still other more preferred compounds of Formula I are those in which

R₁ is ethyl, cyclopropyl, cyclopropylmethyl, *t*-butyl, or phenyl, optionally substituted by F, Cl, OR, or N(R)₂.

Other still more preferred compounds are those of Formula I, wherein adjacent groups R₅-R₈ form a 5- or 6-membered ring having 1 to 2 heteroatoms and which may be substituted by any of the groups described above for R₇;

n is 0 to 1;

R is H, a straight or branched alkyl of 1 to 4 carbons, a ring of 3 to 6 atoms having 0 to 2 heteroatoms or a phenyl, optionally substituted by F, Cl, OH, CN, NO₂, or NH₂; and

-9-

X and Y are independently carbon or nitrogen with the understanding that if X or Y is nitrogen, no substituent R₆ or R₈ is attached.

Other still more preferred compounds are those of Formula I wherein R₁ and R₈ form a 6-membered ring having 1 to 2 heteroatoms and where the ring
5 is optionally substituted with H, CH₃, CH₂CH₃, F, or OCH₃;

R is H, a straight or branched alkyl of 1 to 3 atoms or phenyl optionally substituted by F, Cl, OH, or NH₂;

R₅ and R₆ are each independently H, F, Cl, Br, NO₂, NH₂, CH₃, CHCH₂ or R₅ and R₆ may form a ring of 5 to 7 atoms having 0 to 2 heteroatoms;

10 R₇ is selected from R₅, R₆ and R₈, cyclopropane, cyclobutane, cyclopentane, cyclohexane, a heterocyclic ring of 4 to 7 atoms, a fused heterocyclic ring of 8 to 10 atoms, or a bicyclic heterocycle of 6 to 9 atoms, each having 1 to 4 heteroatoms, and each of the above may be optionally substituted by one or more of R', F, Cl, (CR₂)_nN(R)₂, (CR₂)_nOR, or O, wherein R' is methyl,
15 ethyl, isopropyl, phenyl, a heterocycle of 5 to 6 atoms having 1 to 2 heteroatoms, each of which may be substituted by F, Cl, CH₃, (CH₂)_nN(R)₂, or OR;

n is an integer of 0 to 3; and

Y may be carbon or nitrogen.

Still other more preferred compounds in the invention are those of
20 Formula I where

R₁ is ethyl, cyclopropyl, or fluorocyclopropyl;

R is H, ethyl, propyl, isopropyl or phenyl, each optionally substituted with F, Cl, OH, or NH₂;

R₅, R₆, and R₈ are each independently H, F, Cl, Br, NO₂, methyl, ethyl, ethylene, or any R₅-R₈ may form a ring of 5 to 6 atoms having 0 to
25 2 heteroatoms;

R₇ is a carbocycle of 3 to 6 atoms, a heterocycle of 5 to 6 atoms having 1 to 2 heteroatoms, a fused heterocycle having 9 atoms and 2 heteroatoms, a bicyclic heterocycle of 6 to 8 atoms having 1 to 2 heteroatoms, each of which may
30 be substituted by one or more of R', F, N(R)₂, CH₂N(R)₂, CH₂CH₂N(R)₂,

-10-

$(\text{CH}_3)\text{N}(\text{R})_2$, $\text{C}(\text{CH}_3)_2\text{N}(\text{R})_2$, CH_2OH , $\text{CH}_2\text{CH}_2\text{OH}$, or OH , wherein R' is methyl, ethyl, or phenyl optionally substituted by any of the above;

Y is carbon; and

X is carbon or nitrogen.

5 Most preferred compounds in the invention are those of Formula I where R_1 is ethyl, cyclopropyl, cyclopropylmethyl, *t*-butyl, or phenyl, optionally substituted by F, OH, or $\text{N}(\text{R})_2$;

R is H, methyl, or ethyl;

10 R' is methyl, ethyl, isopropyl, phenyl, a heterocycle of 5 to 6 atoms containing 1 to 2 heteroatoms, each of which may be substituted by F, Cl, CH_3 , $(\text{CH}_2)_n\text{N}(\text{R})_2$, or OR;

R_5 is H, F, or NH_2 ;

R_6 is H, F, Cl, Br, OCH_3 , $\text{CH}=\text{CH}_2$, or NO_2 ;

R_8 is H, F, Cl, Br, CH_3 , or OCH_3 ;

15 R_7 is a 5- or 6-membered ring heterocycle, having 1 to 2 heteroatoms, optionally substituted by $(\text{C}(\text{R})_2)_n\text{N}(\text{R})_2$; a [4.3.0]-bridged heterocycle, with 1 to 2 heteroatoms, which may be optionally substituted by $(\text{C}(\text{R})_2)_n\text{N}(\text{R})_2$; a [3.1.0]-bridged heterocycle, having 1 heteroatom, which may be optionally substituted by $(\text{C}(\text{R})_2)_n\text{N}(\text{R})_2$; a bridged heterocycle of 7 to 9 atoms having 1 to 20 3 heteroatoms, which may be optionally substituted by $(\text{C}(\text{R})_2)_n\text{NR}_2$, which heterocycles may also be substituted by R' , F, Cl, or OH;

n is 0 to 1;

Y is carbon; and

X is carbon or nitrogen.

25 Still most preferred are compounds:

1-Ethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-Ethyl-6-fluoro-3-hydroxy-7-(4-methyl-piperazin-1-yl)-1H-quinazoline-2,4-dione;

1-Ethyl-6-fluoro-3-hydroxy-7-morpholin-4-yl-1H-quinazoline-2,4-dione;

30 1-Ethyl-6-fluoro-3-hydroxy-7-piperidin-1-yl-1H-quinazoline-2,4-dione;

- 11 -

1-(1-Ethyl-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-ylmethyl]-carbamic acid, tert-butyl ester;

7-(3-Aminomethyl-pyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, hydrochloride;

5 1-Ethyl-6-fluoro-3-hydroxy-7-piperazin-1-yl-1H-quinazoline-2,4-dione;

1-(1-Ethyl-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-methyl-3-ylmethyl]-carbamic acid, tert-butyl ester;

7-(3-Aminomethyl-3-methyl-pyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, hydrochloride;

10 6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(6-Fluoro-3-hydroxy-1H-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid, tert-butyl ester;

6-Fluoro-3-hydroxy-1-methyl-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

15 7-(3-Amino-pyrrolidin-1-yl)-6-fluoro-3-hydroxy-1-methyl-1H-quinazoline-2,4-dione, hydrochloride;

1-(4-Hydroxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

20 1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride;

25 1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride;

30 1-(3-Chloro-4-fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

1-(3-Chloro-4-fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

-12-

1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

5 1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride

1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

10 1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

15 1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

1-(2,4,5-Trifluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

20 1-Cyclopropyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

1-Cyclopropyl-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione, hydrochloride;

1-Ethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

25 1-Ethyl-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

7-(3-Aminopyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-pyrido[2,3-d]pyrimidine-2,4-dione, trifluoroacetate;

30 1-Benzyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

1-Cyclopropyl-6-fluoro-3-hydroxy-7-(pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

-13-

7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione;

7-(3-Aminomethyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate;

5 7-(3-Amino-azetidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate;

(1 α ,5 α ,6 α)7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate;

10 (4 α S-cis)1-Cyclopropyl-6-fluoro-3-hydroxy-7-(octahydro-pyrrolo[3,4-b]pyridin-6-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

8-Fluoro-5-hydroxy-9-pyrrolidin-1-yl-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione, trifluoroacetate;

15 (1 α ,5 α ,6 α)9-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-8-fluoro-5-hydroxy-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione, trifluoroacetate;

1-Cyclopropyl-6,8-difluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

20 1-Ethyl-5,6,8-trifluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-Benzyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-Benzyl-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

25 1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl-pyrrolidin-3-yl]-carbamic acid tert-butyl ester;

1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-7-(ethyl-pyrrolidin-3-yl)methyl-amine-1-yl)-1H-quinazoline-2,4-dione;

30 1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

-14-

1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-
1H-quinazoline-2,4-dione, hydrochloride;

6-Fluoro-1-(4-fluorophenyl)-3-hydroxy-7-pyrrolidin-1-yl-1H-
pyrido[2,3-d]pyrimidine-2,4-dione;

5 1-Butyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-
pyrido[2,3-d]pyrimidine-2,4-dione;

6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1-(4-trifluoromethylphenyl)-1H-
pyrido[2,3-d]pyrimidine-2,4-dione;

10 1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-
pyrido[2,3-d]pyrimidine-2,4-dione;

6-Fluoro-3-hydroxy-1-(4-methylphenyl)-7-pyrrolidin-1-yl-1H-
pyrido[2,3-d]pyrimidine-2,4-dione;

6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1-(3-trifluoromethylphenyl)-1H-
pyrido[2,3-d]pyrimidine-2,4-dione;

15 1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-
pyrido[2,3-d]pyrimidine-2,4-dione;

6-Fluoro-3-hydroxy-1-(4-methoxyphenyl)-7-pyrrolidin-1-yl-1H-
pyrido[2,3-d]pyrimidine-2,4-dione;

20 1-Cyclopropylmethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-
quinazoline-2,4-dione;

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-1H-
pyrido[2,3-d]pyrimidine-2,4-dione, hydrochloride;

25 (1 α ,5 α ,6 α)[3-(1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-
tetrahydropyrido[2,3-d]pyrimidine-7-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic
acid tert-butyl ester;

7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6,8-difluoro-3-
hydroxy-1H-quinazoline-2,4-dione;

7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-3-hydroxy-1H-
quinazoline-2,4-dione;

30 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-
oxa-3a,5-diaza-phenalene-4,6-dione;

-15-

9-(3-Amino-pyrrolidin-1-yl)-3-ethyl-8-fluoro-5-hydroxy-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

5 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

10 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione;

15 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2-methyl-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione;

5-Amino-7-(6-amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6,8-difluoro-3-hydroxy-1H-quinazoline-2,4-dione;

20 5-Amino-7-(3-amino-pyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-3-hydroxy-1H-quinazoline-2,4-dione;

7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-6,8-difluoro-3-hydroxy-1-(2-methyl-butyl)-1H-quinazoline-2,4-dione;

7-(3-Aminomethyl-3-methyl-pyrrolidin-1-yl)-6-fluoro-3-hydroxy-1-(2-methyl-butyl)-1H-quinazoline-2,4-dione;

25 7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

7-(3-Amino-pyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione;

30 7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-8-methoxy-1H-quinazoline-2,4-dione; and

7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-8-methylsulfanyl-1H-quinazoline-2,4-dione.

-16-

Here, the term "alkyl" means a straight or branched hydrocarbon radical having from 1 to 12 carbon atoms unless otherwise specified and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, undecyl, and dodecyl. The alkyl groups may contain one or more sites of unsaturation such as double or triple carbon-carbon bonds. The alkyl group is unsubstituted or substituted by from 1 to 3 substituents selected from F, Cl, Br, OH, NH₂, CN, NO₂, OCH₃, OCH₂CH₂OH, NHCH₃, or N(CH₃)₂.

The term "cycloalkyl" means a hydrocarbon ring which contains from 3 to 12 carbon atoms unless otherwise specified, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and adamantyl. Where possible, the cycloalkyl group may contain double bonds. The cycloalkyl ring may be unsubstituted or substituted by from 1 to 3 substituents selected from alkyl, alkoxy, thioalkoxy all as defined herein, hydroxy, thiol, nitro, halogen, amino, formyl, carboxyl, nitrile, -NH-CO-R, -CO-NHR-, -CO₂R, -COR, aryl, or heteroaryl wherein alkyl (R), aryl, and heteroaryl are defined as herein.

The term "heterocycle" means a heterocyclic radical which is 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isaxazolyl, 3- or 5- 1,2,4-triazolyl, 4- or 5- 1,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridinyl, 3-, 4-, or 5-pyridazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl, 1- or 2-piperazinyl, 2-, 3-, or 4-morpholinyl, 2-, 3-, or 4-thiomorpholinyl, 1-, 2-, or 3-pyrrolidinyl, 2- or 3-tetrahydrofuranyl, 2-, 3-, or 4-tetrahydropyranyl, 2- 3-, or 4-piperidinyl, 1-, 2-, 4-, 5-, or 6-tetrahydropyrimidinyl, 2-dioxolinyl, 2-, 4-, or 5-imidazolidinyl, 1-, 2-, 3-, 4-, 5-, 6-, or 7-indolinyl, unsubstituted or substituted by 1 to 2 substituents selected from alkyl as defined above. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO₂ groups are also included.

-17-


The acids, alcohols, and amines which appear in the invention may have to be protected before or during preparation of the final product.

For purposes of the syntheses of the compounds of the present invention, reactive functional groups present in starting materials, reaction intermediates, or
5 reaction products may be protected during chemical reactions using protecting groups which render the reactive functional groups substantially inert to the reaction conditions (see for example, *Protective Groups in Organic Synthesis*, 2 ed., T. W. Green and P. G. Wuts, John Wiley & Sons, New York, NY 1991). Thus, for example, protecting groups such as the following may be utilized to
10 protect suitable amino, hydroxyl, and other groups of related reactivity: carboxylic acyl groups, such as formyl, acetyl, trifluoroacetyl; alkoxycarbonyl groups, such as ethoxycarbonyl, *t*-butoxycarbonyl (BOC), β,β,β -trichloroethoxycarbonyl (TCEC), β -iodoethoxycarbonyl; aryloxy carbonyl groups, such as benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, phenoxycarbonyl; trialkyl silyl
15 groups, such as trimethylsilyl and *t*-butyldimethylsilyl (TBDMS); and groups such as trityl, tetrahydropyranyl, vinyloxycarbonyl, *o*-nitrophenylsulfenyl, diphenylphosphinyl, *p*-toluenesulfonyl, and benzyl may all be utilized. The protecting group may be removed, after completion of the synthetic reaction of interest, by procedures known to those skilled in the art. For example, a BOC
20 group may be removed by acidolysis, a trityl group by hydrogenolysis, TBDMS by treatment with fluoride ions, and TCEC by treatment with zinc.

Fused heterocyclic rings of from 8 to 10 atoms include but are not limited to 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolinyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-benzo[b]thienyl, 2-, 4-, 5-, 6-, or
25 7-benzoxazolyl, 2-, 4-, 5-, 6-, or 7-benzimidazolyl, 2-, 4-, 5-, 6-, or 7-benzothiazolyl.

Heterocycles include but are not limited to

-18-



In all cases, primary and secondary amines may be substituted by alkyl substituents.

5

Some of the compounds of Formula I are capable of further forming pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the present invention.

-19-

Pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanolic acids, hydroxy alkanolic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzensulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge S.M. et al., "Pharmaceutical Salts," *Journal of Pharmaceutical Science*, 1977;66:1-19).

The acid addition salt of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge S.M., supra., 1977).

The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.

Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.

-20-

Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof.

5 The compounds of the present invention can be prepared and administered in a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds of the present invention can be
10 administered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. It will be obvious to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt of a compound of Formula I.

15 For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders,
20 preservatives, tablet disintegrating agents, or an encapsulating material.

 In powders, the carrier is a finely divided solid which is in a mixture with the finely divided active component.

 In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape
25 and size desired.

 The powders and tablets preferably contain from five or ten to about seventy percent of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax,
30 cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets

-21-

and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water propylene glycol solutions. For parenteral injection liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.

Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or, synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is divided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsules, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

The quantity of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 100 mg preferably 0.5 mg to 100 mg according to the

-22-

particular application and the potency of the active component as determined by a skilled physician. The composition can, if desired, also contain other compatible therapeutic agents.

In therapeutic use as agents for the treatment of infections caused by a bacteria, the compounds utilized in the pharmaceutical method of this invention are administered at the initial dosage of about 0.01 mg to about 100 mg/kg daily. A daily dose range of about 0.01 mg to about 10 mg/kg is preferred. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, the compound being employed.

Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.

The compounds of the present invention can be prepared according to the various synthetic schemes that follow. Protecting groups may be used when appropriate throughout many of the schemes. Although specifically noted in certain schemes, the appropriate use and choice of protecting groups is well known by one skilled in the art, and is not limited to the specific examples below. It is also understood that such groups not only serve to protect chemically reactive sites, but also to enhance solubility or otherwise change physical properties. A good general reference for protecting group preparation and deprotection is "Protecting Groups in Organic Synthesis" by Theodora Green. A number of general reactions such as oxidations and reductions etc. are not shown in detail but can be done by methods understood by one skilled in the art. General transformations are well-reviewed in "Comprehensive Organic Transformation" by Richard Larock, and the series "Compendium of Organic Synthetic Methods" published by Wiley-Interscience. In general, the starting materials were obtained from commercial sources unless otherwise indicated.

The compounds of the invention may be prepared according to the following methods in Schemes 1 to 4. All of the N-hydroxy-quinazoline-2,4-diones may be prepared from appropriately substituted benzoic acids. In

-23-

Scheme 1, the anthranilic acid **1** is the key starting material. Such anthranilic acids are well-known in the art of organic synthesis and numerous methods for their preparation are published. The method employed is taken from Jacobs (*J. Het. Chem.*, 1970;7:1337). Accordingly, compound **1** may be reacted with phosgene (COCl₂) or carbonyldiimidazole (CDI) or other such equivalent in inert solvent such as THF, dioxane, benzene, toluene, or chlorocarbon solvents at temperatures of 0°C to 80°C. The intermediate **2** may be isolated or used as is to react with an O-protected hydroxylamine. Generally, the protecting group is benzyl or p-methoxybenzyl, but any O-protecting group may be employed when desired. Such groups would include tetrahydropropanyl, *t*-butyl, 2-chloroethyl, allyl, alkyl, etc. Compound **3** is then again reacted with phosgene, triphosgene, CDI, or some equivalent to give the quinazoline-2,4-dione **4**. The reaction is carried out in THF or dioxane at 25°C to 150°C. At this point, the protecting group may be removed to give **5** which may represent a final product or may be further embellished. The protecting group may be removed by hydrogenation, acid or base treatment, metal catalysis, or a number of other methods described in protecting group art. When Pro is benzyl, the benzyl may be removed with Pd/BaSO₄ or Pd/C and hydrogen. The *t*-butyl group may be removed by alcoholic HCl, TFA, or TFA in dichloromethane. The allylic groups may be removed by PhSiH₃ and Pd catalyst. Solvents such as alcohol, THF, alcohol/THF, alcohol/THF/DMF, etc. are generally employed. The allyl, benzyl, or *t*-butyl groups may also be removed with boron tris(trifluoroacetate) in TFA (*Angew. Chem. Int. Ed.*, 1973;12:147). Reactions are run at room temperature to 50°C and require 1 to 72 hours. Compound **5** may be further reacted, if R₇ is a leaving group, with various heterocyclic amines. The amines displace the leaving group, generally a F or a Cl to form the product **7**. Other leaving groups would be Br, OCH₃, or nitro. Such chemistry is extremely well-known in the quinolone art and is summarized by Bouzard (Recent Progress in the Chemical Synthesis of Antibiotics, Springer Verlag 1990:249-283). Commonly, acetonitrile, DMF, or DMSO are used as solvents and generally reactions require a co-base such as triethylamine, DBU (1,8-diazobicyclo[5.4.0]undec-7-ene) or excess amine heterocycle. Reactions are carried out at 25°C to 150°C and require 0.5 to 48 hours. Alternatively, the

-24-


heterocyclic amine may be directly reacted with **4** prior to removal of the protecting group. The conditions for the reaction are as described above.

Carbocycles and aryls may also be introduced at R₇ if R₇ is a Br, I, or triflate using palladium catalyzed couplings of tin or boronate carbocycles and aryls.

- 5 Compound **6** may then be deprotected to yield **7** using conditions described above for the conversion of **4** to **5**.

-25-

Scheme 1




-26-

Compounds with structure **1** may be commercially available or synthesized by displacement of a leaving group ortho to the carboxy functional group in compound **10** (structure in Scheme 4) by R_1NH_2 . When R_1 in R_1NH_2 is phenyl or substituted phenyl, then compounds of structure **1** may be prepared from the ortho fluorobenzoic acid **10** using lithium diisopropylamide and the appropriate R_1NH_2 at $-78^\circ C$ to $25^\circ C$ in solvents such as ether or THF.

In Scheme 2, the method of Romine (*Synthesis*, 1994:846) is employed. This method begins with an anthranilic acid ester and requires the protected hydroxylamine to be activated for appendage to the nitrogen bearing R_1 . This activation utilizes $(Cl_3CO)_2CO$ and the protected hydroxylamine in solvents such as benzene, toluene, THF, ether, methylene dichloride, and the like. Protecting groups are those as described above with benzyl being common. Reaction of **8** with the activated hydroxylamine yields **9** which may be converted to **4** by treatment with base in inert solvent. Typically, bases would include alkoxide in alcoholic solvents such as *t*-butoxide in *t*-butanol. Other hindered bases would also be appropriate such as LDA or Li-hexamethyl disilazide. In these latter cases, THF, ether, or DMSO would be suitable solvents. The reaction may be carried out at $10^\circ C$ to $80^\circ C$ for 0.5 to 24 hours. The compound **4** may be converted to **5** or **7** as shown in Scheme 1.


-27-

Scheme 2



-28-

Scheme 3




When R_1 in **4** is hydrogen, an alkyl R_1 group may be introduced as shown in Scheme 3. Such a reaction is well-known in the quinolones art and is described by Bouzard, *supra.*, 1990. Typically, such reactions are carried out in THF, ether, DMSO, alcohol, or DMF. Typical R_1X would include ethyl iodide, ethyl bromide, diethyl sulfate, 2-bromoethanol, and the like. Typical bases would be sodium hydride, potassium carbonate, and the like. Once compound **4** is produced, with R_1 being alkyl, conversion to **5** or **7** may proceed according to Scheme 1.

In certain cases it may be desirable to add the R_1N group late in the synthesis (Scheme 4). Such options are available when starting with a leaving group ortho to the carboxy group such as in the 2-fluoro benzoic acid **10**. The acid **10** may be activated with oxalyl chloride, CDI, thionyl chloride as known in the art and the protected hydroxylamine added to give **11**. Compound **11** is converted to **12** using an isocyanate (OCNR_1) and base, or with heat by a thermal reaction. The isocyanates are well-known starting materials. Typical bases would include NaH, KH, or K_2CO_3 . Solvents would include toluene, xylenes, THF, ether, and the like at -10°C to 150°C . The adduct **12** would then be cyclized according to the methods cited by Bouzard, *supra.*, 1990. Such conditions would include the use of potassium *t*-butoxide, NaH, or the like in THF, DMF, DMSO, or

-29-

other inert solvents at 15°C to 100°C. Cyclization gives **4** which may be converted to **5** and **7** according to Scheme 1.


Scheme 4



- 5 Displacement of leaving groups as shown in Scheme 1 is not limited to nitrogen heterocycles. Other nucleophiles (Nu) such as CH_3O^- , R_2NH , R-NH , and RS^- will also displace a F, Cl, or NO_2 leaving group at R_7 as shown in Scheme 5.

-30-

Scheme 5



Such reactions are carried out at 25°C to reflux in solvents such as acetonitrile, THF, DMF, DMA, and the like. Likewise the reaction may be carried out in a pressure sealed vessel at elevated temperatures up to 150°C. The nucleophiles may be used in excess or, in the case of the amines, as solvents. When the leaving group is a triflate or higher halide, organo tin reagents or organoboronates may be used with palladium catalysts to deliver a carbon nucleophile. In this manner, all sorts of alkyl and aryl groups may be represented by Nu such as methyl, ethyl, vinyl, cyclopentyl, cyclopentenyl, and the like. The methodology follows that of Stille, et al. (*Agnew. Chem. Int. Ed. Eng.*, 1986;25:508) and is exemplified by Mitchell (*Synthesis*, 1992:803). This method is well-known in the art as is the preparation of triflates and the tin reagents.

All of the chemistry depicted and described in Schemes 1 to 5 would apply using the definitions of X and Y in Formula I. When either X or Y is nitrogen, the displacement chemistry would indeed be more facile than when X and Y are carbon.


In Scheme 6, synthetic methodologies to prepare compounds where two adjacent R groups form a ring are shown. The alkylations such as in the preparation of **15** or **16** are carried out with inert bases such as K₂CO₃, Cs₂CO₃, NaHCO₃, and the like. Solvents are typically dioxane, DMF, DMA, DMSO, and the like. Temperatures are 25°C to 125°C. The reaction of **17** to **18** is carried out at RT to 125°C in solvents such as dioxane, DMF, and the like.

-31-

The reactions of **14** and **17** would also work for amine or thiol substituents and their relative position on the quinazoline ring system would not affect the chemistry. This is not so for the preparation of **20** since it involves a displacement of R₇. In this reaction, any primary amine may be employed in solvents such as dioxane, acetonitrile, DMSO, or DMF. The use of pressure-sealed vessels may be employed for volatile amines. The reaction may be carried out at 25°C to 125°C.

-32-

Scheme 6




-33-

Compounds of the invention where X and/or Y of General Formula I are nitrogen may be prepared by the Schemes 1, 2, 3, and 5 or by routes which take advantage of the activation of leaving groups ortho and para to the nitrogen. Such routes will systematically introduce the groups labeled R₇ and R₁ in the General
5 Formula I. This methodology also applies to cases in Formula I where X is CH or CF and Y is CF.

Such systematic substitutions are demonstrated in Scheme 7. The pyridine ester **21** has leaving groups on both sides of the nitrogen. Such groups are generally chlorine, but fluorine, thiols, and thiolates are also good leaving groups
10 in such compounds. These leaving groups may be sequentially displaced based on reactivity. In Scheme 7, where Y = N or CF, the 6-chloro of **21** is displaced preferentially using a nucleophilic amine such as diethylamine, pyrrolidine, methylpiperazine and the like to give **22**. An inert base such as triethylamine, DBU, or the like is employed to take up the HCl that is generated in the reaction.
15 The reaction is performed in acetonitrile, DMF, DMA or the like at 0°C to 100°C. Compound **22** is then reacted with R₁NH₂ to displace the second leaving group. The reaction may be carried out with excess R₁NH₂ or with inert bases described above. Typical solvents are acetonitrile, THF, DMF, DMA or the like at temperatures from 0°C to 100°C. The ester **23** is then hydrolyzed by any
20 conditions known in the art, to the acid **24** which is then coupled by one of several amide forming reactions well-known in the art which activate the acid. Such methods would include acid chloride forming reagents, mixed anhydrides, carbonyldiimidazole (CDI), dicyclohexylcarbodiimide (DCC) or, activated esters such as para nitrophenol, pentafluorophenol, or hydroxybenztriazole with DCC or
25 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDCI). The NHO-benzyl amide **25** is then reacted with CDI, phosgene, or a phosgene equivalent to form the cyclized O-protected product **26**. Typical solvents are ether, THF, DMF, and the like, and typical temperatures are 15°C to 100°C. The reaction sequence taking
30 **25** to **26** is identical to that described in Scheme 1 for the conversion of **3** to **4**. Deprotection of the O-benzyl groups proceeds as described above to give the final products **27**.

-34-

Scheme 7



-35-


Another method for compounds of type I where X and/or Y are nitrogen in Formula I is patterned after Scheme 4. In Scheme 8, the NHO-benzyl amide **29** is prepared from **28** by one of the amide forming methods known in the art as described above. The NH of the NHO-benzyl of compound **29** is then

5 deprotonated with an inert base such as sodium hydride, potassium hydride, and the like in solvents such as THF, DMF, or DMA at -78°C to 50°C. The reaction mixture is then reacted with an isocyanate, RNCO, which captures the NO-benzyl anion and cyclizes in one pot. Compound **30** is then reacted, if desired, with various nucleophiles according to the conditions in Scheme 5 to give **26**.

10 Deprotection of **26** follows the methods described above to give **27**.

-36-

Scheme 8




-37-

Tricyclic compounds (where R₁ and R₈ form a ring in Structure I) can be prepared according to Schemes 9 and 10. Schemes 9 and 10 differ in the introduction of the R₁ substitutions in **36** and **42** wherein R₁ and R₁' are defined as for Structure I. In Scheme 9, the ortho fluoro nitro compound **31** serves as the starting material taking advantage of the activated fluorine toward displacement with a nucleophile: X. Other leaving groups such as chlorine, bromine, and sulfonyl may also be employed. The α -nucleophile substituted ester displaces the fluorine at temperatures 0°C to 150°C in solvents such as DMF, DMA, DMSO, acetonitrile and the like. The nitro group is then reduced using Raney Ni, H₂ over Pd/C, or with an active metal in acid such as iron or tin in HCl or acetic acid. The newly formed amine readily cyclizes on the ester to form **32**. Other acid analogs may be employed such as esters, thio esters, amides and the like. Compound **32** is then reduced with hydride reducing agents such as LiAlH₄ and the like to produce compound **33**. It is recognized that R₁ and R₁' may form a chiral center giving R and S enantiomers. Such enantiomers may be separated, if desired, by chiral HPLC at any stage or by chemical resolution using mandelic acid, tartaric acid, or other chiral, optically pure acid bearing resolving agents. Chiral amides may also be employed such as the camphorsulfonamide, mandelamide, or the like. The quinazolinodione ring is prepared sequentially by first reacting **33** with chloral hydrate which forms the dione ring in **34**. Compound **34** is ring opened using sodium hydroxide and hydrogen peroxide to give the benzoic acid which is cyclized with carbonyldiimidazole or a phosgene equivalent according to Scheme 1 to give the final product **36**.

-38-

Scheme 9




-39-

In a similar series of reactions, Scheme 10 utilizes the already reduced version of **31**. Thus, the aniline **37** is reacted with an α -nucleophile substituted ketone. In this sequence the aniline forms a cyclic imine, which is reduced with H₂ on Pd/C or by chemical hydride reducing agents such as sodium borohydride or sodium cyanoborohydride to give **39**. Such reductive aminations are well-known in the art and are typically performed in alcohol, water alcohol mixtures, or in water DMF mixtures at temperatures of 0°C to 80°C. Again, the chiral centers may be resolved as discussed above. The remaining steps to produce **42** follow those of Scheme 9 for the conversion of **33** to **36**. When R₇ is a leaving group, compounds **36** and **42** may be further reacted with nucleophiles to give compounds of Formula I as in the previous schemes.

-40-

Scheme 10



-41-


In Scheme 11, the target tricyclic compounds as **42** are prepared in a slightly different manner. In this case, the nucleophile X is attached to the phenyl ring, and the leaving group L is attached alpha to the ketone. The nucleophile may be activated with bases such as sodium hydride or potassium hydride in solvents such as ether, THF, or DMF and the like at temperatures of 10°C to 50°C.

Alternate bases may be triethylamine or DBU in solvents such as ether, THF, acetonitrile, DMF or the like at temperatures of 25°C to 100°C. Still other bases would include sodium or potassium carbonate in alcoholic solvents or DMF at temperatures of 25°C to 100°C. Once compound **38** is obtained, the rest of

Scheme 11 follows that of Scheme 10.


-42-

Scheme 11



-43-

The kinds of nitrogen heterocycles envisioned for Scheme 1 are exemplified but not limited to those shown below:



5 All of these nitrogen heterocycles are known in the art and are prepared by literature methods such as *J. Med. Chem.*, 1992;35:1764; *J. Med. Chem.*, 1996;39:3070; *Synlett.*, 1996:1097; and *J. Med. Chem.*, 1986;29:445. Any of the primary or secondary amines may be substituted by alkyl.

-44-

Example A

2-Amino-N-benzyloxy-4,5-difluoro-benzamide

Carbonyldiimidazole (6.1 g, 37 mmol) was added to a suspension of 4,5-difluoroanthranilic acid (5.40 g, 31 mmol) in 250 mL of THF, and the mixture was stirred for 24 hours at 25°C. O-benzylhydroxylamine hydrochloride (4.95 g, 31 mmol) and triethylamine (5.2 mL, 37 mmol) were added, and the mixture was heated to reflux for 4 hours. The reaction mixture was concentrated and washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution was concentrated to give 6.0 g of the title compound as a solid, mp 125-126°C.

Example B

3-Benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

Phosgene, 12.5% solution in toluene, (16 mL, 20 mmol) was added to a solution of 2-amino-N-benzyloxy-4,5-difluoro-benzamide (Example A, 5.54 g, 19.9 mmol) in 160 mL of dioxane. The solution was heated at reflux for 5 hours and then poured into 450 mL of water. The aqueous solution was extracted with ethyl acetate; the combined organic extracts were washed with water, brine, and dried over magnesium sulfate. The solution was concentrated to give 5.73 g of the title compound as a solid, mp >250°C.

Example C

3-Benzyloxy-1-ethyl-6,7-difluoro-1H-quinazoline-2,4-dione

A solution of 3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example B, 3.0 g, 9.9 mmol) in 100 mL of DMF was added to a suspension of sodium hydride (0.47 g, 11.8 mmol) in 40 mL of DMF and stirred for 30 minutes. Ethyl iodide (7.9 mL, 99 mmol) was added, and the mixture was warmed to 50°C for 18 hours. The reaction was quenched with 1 mL of water and concentrated to an oil. The residue was dissolved in chloroform washed with water, brine, and dried over magnesium sulfate. The solution was concentrated to give 3.2 g of the title compound as a solid, mp 133-135°C.

-45-

Example D

1-Ethyl-6,7-difluoro-3-hydroxy-1H-quinazoline-2,4-dione

Twenty percent Pd/C was added to a solution of 3-benzyloxy-1-ethyl-6,7-difluoro-1H-quinazoline-2,4-dione (Example C, 0.055 g, 0.16 mmol) in 25 mL of THF and 25 mL of methanol. This was shaken under 50 PSI of hydrogen for 12.5 hours. The mixture was filtered and concentrated to afford 0.03 g of the title compound as a solid, mp 172-174°C.

Example E

3-Benzyloxy-1-ethyl-6-fluoro-7-pyrrolidinyl-1H-quinazoline-2,4-dione

Pyrrolidine (0.06 mL, 0.72 mmol) was added to a solution of 3-benzyloxy-1-ethyl-6,7-difluoro-1H-quinazoline-2,4-dione (Example C, 0.2 g, 0.6 mmol) and triethylamine (0.17 mL, 1.2 mmol) in 30 mL of acetonitrile. The solution was warmed to reflux for 3 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform, washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.21 g of the title compound as a solid, mp 174-176°C.

Example F

3-Benzyloxy-1-ethyl-6-fluoro-7-piperazinyl-1H-quinazoline-2,4-dione

Piperazine (0.06 g, 0.72 mmol) was added to a solution of 3-benzyloxy-1-ethyl-6,7-difluoro-1H-quinazoline-2,4-dione (Example C, 0.2 g, 0.6 mmol) and triethylamine (0.17 mL, 1.2 mmol) in 30 mL of acetonitrile. The solution was warmed to reflux for 24 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.13 g of the title compound as a solid, mp 166-167°C.

Example G

3-Benzyloxy-1-ethyl-6-fluoro-7-morpholino-1H-quinazoline-2,4-dione

Morpholine (0.06 mL, 0.72 mmol) was added to a solution of 3-benzyloxy-1-ethyl-6,7-difluoro-1H-quinazoline-2,4-dione (Example C, 0.2 g,

-46-

0.6 mmol) and triethylamine (0.17 mL, 1.2 mmol) in 30 mL of acetonitrile. The solution was warmed to reflux for 100 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution was concentrated to give
5 0.21 g of a solid. The solid was purified by column chromatography (chloroform/methanol 99:1). The appropriate fractions were combined to give 0.17 g of the title compound as a solid.

NMR (CDCl₃): δ 7.80 (d, 1H), 7.59 (m, 2H), 7.34 (m, 3H), 6.49 (d, 1H), 5.17 (s, 2H), 4.14 (q, 2H), 3.87 (m, 4H), 3.23 (m, 4H), 1.33 (t, 3H).

10

Example H

3-Benzoyloxy-1-ethyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-1H-quinazoline-2,4-dione

4-Methylpiperazine (0.08 mL, 0.72 mmol) was added to a solution of 3-benzoyloxy-1-ethyl-6,7-difluoro-1H-quinazoline-2,4-dione (Example C, 0.2 g, 0.6 mmol) and DBU (0.09 mL, 0.6 mmol) in 30 mL of acetonitrile. The solution
15 was warmed to reflux for 100 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with water, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.21 g of a solid. The solid was purified by column chromatography (chloroform/methanol 99:1). The appropriate
20 fractions were combined to give 0.14 g of the title compound as a solid.
mp 134-136°C.

Example I

3-Benzoyloxy-6-fluoro-7-pyrrolidinyl-1H-quinazoline-2,4-dione

Pyrrolidine (0.065 mL, 0.8 mmol) was added to a solution of 3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example B, 0.2 g, 0.65 mmol) and triethylamine (0.18 mL, 1.2 mmol) in 30 mL of acetonitrile. The solution was warmed to reflux for 18 hours, cooled, and filtered to give 0.2 g of the title
25 compound as a solid, mp >250°C.

-47-

Example J

1-(3-Benzyloxy-6-fluoro-1H-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid, tert-butyl ester

5 N-Boc-3-aminopyrrolidine (0.21 g, 1.8 mmol) was added to a solution of 3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example B, 0.2 g, 0.65 mmol) and triethylamine (0.27 mL, 1.8 mmol) in 30 mL of acetonitrile. The solution was warmed to reflux for 120 hours, cooled, and filtered to give 0.22 g of the title compound as a solid, mp >250°C.

Example K

10 3-Benzyloxy-6,7-difluoro-1-methyl-1H-quinazoline-2,4-dione

A solution of 3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example B, 1.5 g, 5 mmol) in 50 mL of DMF was added to a suspension of sodium hydride (0.24 g, 5.9 mmol) in 20 mL of DMF and stirred for 30 minutes. Methyl iodide (3.1 mL, 49 mmol) was added, and the mixture was stirred at 25°C
15 for 18 hours. The reaction was quenched with 1 mL of water and concentrated to an oil. The residue was dissolved in chloroform, washed with water, brine, and dried over magnesium sulfate. The solution was concentrated to give 1.6 g of the title compound as a solid, mp 167-169°C.

Example L

20 6,7-Difluoro-3-hydroxy-1-methyl-1H-quinazoline-2,4-dione

Twenty percent Pd/C (0.2 g) was added to a solution of 3-benzyloxy-6,7-difluoro-1-methyl-1H-quinazoline-2,4-dione (Example K, 1.55 g, 4.9 mmol) in 25 mL of THF and 25 mL of methanol. The mixture was shaken under 50 PSI of hydrogen for 1.5 hours, and filtered. The catalyst was rinsed with 200 mL of a
25 50/50 mixture of THF and methanol and concentrated to afford 1.1 g of the title compound as a solid, mp 239-241°C.

General Method 1. A procedure for the preparation of 2-substituted phenylamino-benzoic acids

30 A 2.5 M solution of n-butyl lithium (n-BuLi) in hexanes (3.1 equivalents) was added at -5°C to a solution of diisopropylamine (3 equivalents) in 150 mL of

-48-

dry THF under nitrogen, and the mixture was stirred for 30 minutes. The reaction mixture was cooled to -78°C and the appropriate aniline (1 equivalent) was added. The reaction mixture was stirred for 30 minutes, then a solution of a 2-fluorobenzoic acid (1 equivalent) in 50 mL of dry THF was added, and the reaction mixture was allowed to warm to room temperature overnight. Water (100 mL) was added, and the reaction mixture was concentrated, acidified with concentrated HCl to pH 1, and extracted with ether (3 × 100 mL). Combined ether extracts were washed with 1N hydrochloric acid, water and brine, and dried over sodium sulfate. Solvents were evaporated to give the product as a solid.

10

Example M

2-(4-Hydroxy-anilino)-4,5-difluoro-benzoic acid

Using General Method 1, the reaction of 2.5 M solution of n-BuLi in hexanes (29 mL, 73 mmol), diisopropylamine (9.5 mL, 68 mmol), 4-hydroxyaniline (1.85 g, 17 mmol), and 2,4,5-trifluorobenzoic acid (3 g, 17 mmol) provided 4.5 g of the crude title compound.

15

Example N

2-(4-Fluoro-anilino)-4,5-difluoro-benzoic acid

Using General Method 1, the reaction of 2.5 M solution of n-BuLi in hexanes (14 mL, 35 mmol), diisopropylamine (4.8 mL, 34 mmol), 4-fluoro-aniline (1.1 mL, 11 mmol), and 2,4,5-trifluorobenzoic acid (2 g, 11 mmol) provided 2.59 g of the crude title compound.

20

Example O

2-(4-Methoxy-anilino)-4,5-difluoro-benzoic acid

Using General Method 1, the reaction of 2.5 M solution of n-BuLi in hexanes (26 mL, 64 mmol), diisopropylamine (8.7 mL, 62 mmol), 4-methoxy-aniline (2.6 g, 17 mmol), and 2,4,5-trifluorobenzoic acid (3.6 g, 20.7 mmol) provided 5.72 g of the crude title compound.

25

-49-

Example P

2-(3-Chloro-4-fluoro-anilino)-4,5-difluoro-benzoic acid

Using General Method 1, the reaction of 2.5 M solution of n-BuLi in hexanes (21 mL, 53 mmol), diisopropylamine (7.2 mL, 51 mmol), 3-chloro-4-fluoro-aniline (2.48 mL, 17 mmol), and 2,4,5-trifluorobenzoic acid (3.0 g, 17 mmol) provided 4.32 g of the crude title compound.

Example Q

2-(3-Methoxy-anilino)-4,5-difluoro-benzoic acid

Using General Method 1, the reaction of 2.5 M solution of n-BuLi in hexanes (21 mL, 53 mmol), diisopropylamine (7.2 mL, 51 mmol), 3-methoxy-aniline (1.91 mL, 17 mmol), and 2,4,5-trifluorobenzoic acid (3.0 g, 17 mmol) provided 4.48 g of the crude title compound.

Example R

2-(2-Fluoro-anilino)-4,5-difluoro-benzoic acid

Using General Method 1, the reaction of 2.5 M solution of n-BuLi in hexanes (21 mL, 53 mmol), diisopropylamine (7.2 mL, 51 mmol), 2-fluoro-aniline (1.6 mL, 17 mmol), and 2,4,5-trifluorobenzoic acid (3.0 g, 17 mmol) provided 4.08 g of the crude title compound.

Example S

2-(3-Fluoro-anilino)-4,5-difluoro-benzoic acid

Using General Method 1, the reaction of 2.5 M solution of n-BuLi in hexanes (21 mL, 53 mmol), diisopropylamine (7.2 mL, 51 mmol), 3-fluoro-aniline (1.6 mL, 17 mmol), and 2,4,5-trifluorobenzoic acid (3.0 g, 17 mmol) provided 4.24 g of the crude title compound.

Example T

2-(2,4,5-Trifluoro anilino)-4,5-difluoro-benzoic acid

Using General Method 1, the reaction of 2.5 M solution of n-BuLi in hexanes (21 mL, 53 mmol), diisopropylamine (7.2 mL, 51 mmol), 2,4,5-trifluoro-

-50-

aniline (2.5 g, 17 mmol), and 2,4,5-trifluorobenzoic acid (3.0 g, 17 mmol) provided 4.54 g of the crude title compound.

General Method 2. A procedure for the preparation of 2-substituted phenylamino-N-benzyloxy-benzamides

5 Carbonyldiimidazole (1.1 equivalent) was added to a solution of substituted 2-(anilino)-benzoic acids (1.0 equivalent) in 250 mL of THF, and the mixture was stirred for 24 hours at 25°C. O-benzylhydroxylamine hydrochloride (1 equivalent) and triethylamine (1.1 equivalent) were added, and the mixture was heated to reflux for 4 hours. The reaction mixture was concentrated diluted with
10 ether and washed with 1N HCl, saturated NaHCO₃, brine, and dried over sodium sulfate. The solution was concentrated to give the product as an oil.

Example U

2-(4-Fluoro-anilino)-N-benzyloxy-4,5-difluoro-benzamide

Using General Method 2, the reaction of carbonyldiimidazole (1.90 g, 11.6 mmol), 2-(4-fluoro-anilino)-4,5-difluorobenzoic acid (Example N, 2.59 g, 9.7 mmol), O-benzylhydroxylamine hydrochloride (1.55 g, 9.7 mmol), and triethylamine (1.63 mL, 11.6 mmol) provided 3.43 g of the crude title compound.

Example V

2-(4-Methoxy-anilino)-N-benzyloxy-4,5-difluoro-benzamide

20 Using General Method 2, the reaction of carbonyldiimidazole (3.6 g, 22.4 mmol), 2-(4-methoxy-anilino)-4,5-difluorobenzoic acid (Example O, 5.72 g, 20.4 mmol), O-benzylhydroxylamine hydrochloride (3.26 g, 20.4 mmol), and triethylamine (3.1 mL, 22.4 mmol) provided 8.0 g of the crude title compound.

Example W

25 2-(3-Chloro-4-fluoro-anialino)-N-benzyloxy-4,5-difluoro-benzamide

Using General Method 2, the reaction of carbonyldiimidazole (2.60 g, 15.7 mmol), 2-(3-chloro-4-fluoro-anilino)-4,5-difluorobenzoic acid (Example P, 4.32 g, 14.3 mmol), O-benzylhydroxylamine hydrochloride (2.3 g, 14.3 mmol),

-51-

and triethylamine (2.2 mL, 15.7 mmol) provided 6.1 g of the crude title compound.

Example X

2-(3-Methoxy-anilino)-N-benzyloxy-4,5-difluoro-benzamide

5 Using General Method 2, the reaction of carbonyldiimidazole (2.90 g, 17.6 mmol), 2-(3-methoxy-anilino)-4,5-difluorobenzoic acid (Example Q, 4.48 g, 16 mmol), O-benzylhydroxylamine hydrochloride (2.6 g, 16 mmol), and triethylamine (2.5 mL, 17.6 mmol) provided 6.5 g of the crude title compound.

Example Y

10 2-(2-Fluoro-anilino)-N-benzyloxy-4,5-difluoro-benzamide

 Using General Method 2, the reaction of carbonyldiimidazole (2.76 g, 16.8 mmol), 2-(2-fluoro-anilino)-4,5-difluorobenzoic acid (Example R, 4.08 g, 15.3 mmol), O-benzylhydroxylamine hydrochloride (2.44 g, 15.3 mmol), and triethylamine (2.3 mL, 16.8 mmol) provided 5.6 g of the crude title compound.

15 Example Z

2-(3-Fluoro-anilino)-N-benzyloxy-4,5-difluoro-benzamide

 Using General Method 2, the reaction of carbonyldiimidazole (2.83 g, 17.5 mmol), 2-(3-fluoro-anilino)-4,5-difluorobenzoic acid (Example S, 4.24 g, 15.9 mmol), O-benzylhydroxylamine hydrochloride (2.5 g, 15.9 mmol), and
20 triethylamine (2.4 mL, 17.5 mmol) provided 5.4 g of the crude title compound.

Example A-1

2-(2,4,5-Trifluoroanilino)-N-benzyloxy-4,5-difluoro-benzamide

 Using General Method 2, the reaction of carbonyldiimidazole (2.85 g, 17.6 mmol), 2-(2,4,5-trifluoro-anilino)-4,5-difluorobenzoic acid (Example T, 4.54 g, 14.7 mmol), O-benzylhydroxylamine hydrochloride (2.34 g, 14.7 mmol), and triethylamine (2.45 mL, 17.6 mmol) provided 6.22 g of the crude title
25 compound.

-52-

General Method 3. A procedure for the preparation of 1-substituted phenyl-3-benzyloxy-1H-quinazoline-2,4-diones

Carbonyldiimidazole (2 equivalents) was added to a solution of 2-substituted aniline-N-benzyloxy-benzamide (1 equivalent) in 160 mL of THF. The solution was heated at reflux overnight, solvent was evaporated, the residue was dissolved in ethyl acetate and washed with water, 1N HCl, water, brine, and dried over sodium sulfate. The solution was concentrated to give the crude product, which was then purified on silica gel column using a 1/6 (v/v) mixture of ethyl acetate and hexanes, to provide crystalline product.

5

Example B-11-(4-Fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

Using General Method 3, the reaction of carbonyldiimidazole (3.0 g, 18.4 mmol) and crude 2-(4-fluoro-anilino)-N-benzyloxy-4,5-difluoro-benzamide (Example U, 3.43 g, 9.2 mmol) provided 1.8 g of the title compound as a solid, mp 201-202°C.

15

Example C-11-(4-Methoxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

Using General Method 3, the reaction of carbonyldiimidazole (6.7 g, 41.6 mmol) and crude 2-(4-methoxy-anilino)-N-benzyloxy-4,5-difluoro-benzamide (Example V, 8.0 g, 20.8 mmol) provided 3.86 g of the title compound as a solid, mp 211-212°C.

20

Example D-11-(3-Chloro-4-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

Using General Method 3, the reaction of carbonyldiimidazole (4.9 g, 30 mmol) and crude 2-(3-chloro-4-fluoro-anilino)-N-benzyloxy-4,5-difluoro-benzamide (Example W, 6.1 g, 15 mmol) provided 1.27 g of the title compound as a solid, mp 184-186°C.

25

-53-

Example E-1

1-(3-Methoxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

Using General Method 3, the reaction of carbonyldiimidazole (5.5 g, 33.8 mmol) and crude 2-(3-methoxy-anilino)-N-benzyloxy-4,5-difluoro-benzamide (Example X, 6.5 g, 16.9 mmol) provided 1.3 g of the title compound as a solid, mp 157-158°C.

Example F-1

1-(2-Fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

Using General Method 3, the reaction of carbonyldiimidazole (4.9 g, 30 mmol) and crude 2-(2-fluoro-anilino)-N-benzyloxy-4,5-difluoro-benzamide (Example Y, 5.6 g, 15 mmol) provided 2.9 g of the title compound as a solid, mp 204-206°C.

Example G-1

1-(3-Fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

Using General Method 3, the reaction of carbonyldiimidazole (4.7 g, 29 mmol) and crude 2-(3-fluoro-anilino)-N-benzyloxy-4,5-difluoro-benzamide (Example Z, 5.4 g, 14.5 mmol) provided 1.8 g of the title compound as a solid, mp 179-181°C.

Example H-1

1-(2,4,5-Trifluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

Using General Method 3, the reaction of carbonyldiimidazole (4.9 g, 30.4 mmol) and crude 2-(2,4,5-trifluoro-anilino)-N-benzyloxy-4,5-difluoro-benzamide (Example A-1, 6.22 g, 15.2 mmol) provided 0.35 g of the title compound as a solid.

25

Example I-1

2-(4-Hydroxyanilino)-N-benzyloxy-4,5-difluoro-benzamide

1-Ethyl-3-(3'-dimethylaminopropyl)carbodiimide (EDCI, 0.22 g, 1.1 mmol) and HOBt (0.17 g, 1.1 mmol) were added to a solution of crude 2-(4-hydroxyanilino)-4,5-difluoro-benzoic acid (Example M, 0.265 g, 1.00 mmol) in

-54-

70 mL of dichloromethane at 0°C. After 1 hour, O-benzylhydroxylamine hydrochloride (0.176 g, 1.1 mmol), and triethylamine (0.15 mL, 1.1 mmol) were added, and the reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with 100 mL of ether and washed with water and 0.1N HCl, water, and brine, dried over sodium sulfate. Solvents were evaporated to give 0.35 g of the title compound as a crude solid.

Example J-1

1-(4-Hydroxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

A 2N solution of phosgene in toluene (2.5 mL, 5 mmol) was added to a solution of crude 2-(4-hydroxyanilino)-N-benzyloxy-4,5-difluoro-benzamide (Example I-1, 0.35 g, 0.95 mmol) in 20 mL of dioxane. The solution was heated at reflux for 2 hours, cooled down to room temperature and poured into ice water, and extracted with ethyl acetate (3 × 30 mL). Combined extracts were washed with water, brine, and dried over sodium sulfate to give 0.065 g of the title product as a solid.

General Method 4. A procedure for the reaction of 1-(substituted phenyl)-3-benzyloxy-1H-quinazoline-2,4-diones with amine nucleophiles

The amine nucleophile (3 equivalents) was added to a solution of 1-(substituted phenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (1.0 equivalent) and triethylamine (3 equivalents) in 7 mL of dimethylacetamide (DMA). The solution was heated at 70°C for 1.5 hours, cooled, and poured into water. The precipitate which formed was collected by filtration, washed with water, and dried to provide the product as a solid.

Example K-1

1-(4-Hydroxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Using General Method 4, the reaction of pyrrolidine (0.04 mL, 0.5 mmol), triethylamine (0.07 mL, 0.5 mmol), and 1-(4-hydroxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example J-1, 0.065 g, 0.16 mmol) provided 0.05 g of the title compound as a solid.

-55-

Example L-1

1-(4-Fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

5 Using General Method 4, the reaction of pyrrolidine (0.07 mL, 0.92 mmol), triethylamine (0.08 mL, 0.92 mmol), and 1-(4-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example B-1, 0.127 g, 0.31 mmol) provided 0.087 g of the title compound as a solid.

Example M-1

10 1-(4-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

Using General Method 4, the reaction of N-methylpiperazine (0.14 mL, 1.23 mmol), triethylamine (0.17 mL, 1.23 mmol), and 1-(4-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example B-1, 0.163 g, 0.41 mmol) provided 0.19 g of the title compound as a solid.

15 Example N-1

1-(4-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(3-*t*-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione

20 Using General Method 4, the reaction of 3-*t*-butoxycarbonylamino-pyrrolidine (0.28 g, 1.5 mmol), triethylamine (0.2 mL, 1.5 mmol), and 1-(4-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example B-1, 0.2 g, 0.5 mmol) provided 0.225 g of the title compound as a solid.

Example O-1

1-(4-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

25 Using General Method 4, the reaction of pyrrolidine (0.125 mL, 1.5 mmol), triethylamine (0.2 mL, 1.5 mmol), and 1-(4-methoxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example C-1, 0.20 g, 0.5 mmol) provided 0.21 g of the title compound as a solid.

-56-

Example P-1

1-(4-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

5 Using General Method 4, the reaction of N-methylpiperazine (0.17 mL, 1.5 mmol), triethylamine (0.2 mL, 1.5 mmol), and 1-(4-methoxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example C-1, 0.20 g, 0.5 mmol) provided 0.19 g of the title compound as a solid.

Example Q-1

10 1-(4-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-(3-*t*-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione

Using General Method 4, the reaction of 3-*t*-butoxycarbonylamino-pyrrolidine (0.28 g, 1.5 mmol), triethylamine (0.2 mL, 1.5 mmol), and 1-(4-methoxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example C-1, 0.2 g, 0.5 mmol) provided 0.25 g of the title compound as a solid.

15 Example R-1

1-(3-Chloro-4-fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

20 Using General Method 4, the reaction of N-methylpiperazine (0.12 mL, 1 mmol), triethylamine (0.14 mL, 1 mmol), and 1-(3-chloro-4-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example D-1, 0.14 g, 0.32 mmol) provided 0.14 g of the title compound as a solid.

Example S-1

1-(3-Chloro-4-fluoro-phenyl)-6-fluoro-3-benzyloxy-7-(3-*t*-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione

25 Using General Method 4, the reaction of 3-*t*-butoxycarbonylamino-pyrrolidine (0.187 g, 1 mmol), triethylamine (0.14 mL, 1 mmol), and 1-(3-chloro-4-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example D-1, 0.14 g, 0.32 mmol) provided 0.25 g of the title compound as a solid.

-57-

Example T-1

1-(3-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

5 Using General Method 4, the reaction of pyrrolidine (0.077 mL, 0.9 mmol), triethylamine (0.12 mL, 0.9 mmol), and 1-(3-methoxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example E-1, 0.12 g, 0.3 mmol) provided 0.12 g of the title compound as a solid.

Example U-1

10 1-(3-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

Using General Method 4, the reaction of N-methylpiperazine (0.1 mL, 0.9 mmol), triethylamine (0.12 mL, 0.9 mmol), and 1-(3-methoxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example E-1, 0.12 g, 0.3 mmol) provided 0.12 g of the title compound as a solid.

15 Example V-1

1-(3-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione

20 Using General Method 4, the reaction of 3-t-butoxycarbonylamino-pyrrolidine (0.162 g, 0.9 mmol), triethylamine (0.12 mL, 0.9 mmol), and 1-(3-methoxyphenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example E-1, 0.12 g, 0.3 mmol) provided 0.15 g of the title compound as a solid.

Example W-1

1-(2-Fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

25 Using General Method 4, the reaction of pyrrolidine (0.063 mL, 0.75 mmol), triethylamine (0.106 mL, 0.75 mmol), and 1-(2-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example F-1, 0.1 g, 0.25 mmol) provided 0.1 g of the title compound as a solid.

-58-

Example X-1

1-(2-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

5 Using General Method 4, the reaction of N-methylpiperazine (0.083 mL, 0.75 mmol), triethylamine (0.106 mL, 0.75 mmol), and 1-(2-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example F-1, 0.1 g, 0.25 mmol) provided 0.12 g of the title compound as a solid.

Example Y-1

10 1-(3-Fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Using General Method 4, the reaction of pyrrolidine (0.1 mL, 1.28 mmol), triethylamine (0.18 mL, 1.28 mmol), and 1-(3-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example G-1, 0.17 g, 0.43 mmol) provided 0.1 g of the title compound as a solid.

15 Example Z-1

1-(3-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

20 Using General Method 4, the reaction of N-methylpiperazine (0.16 mL, 1.43 mmol), triethylamine (0.2 mL, 1.43 mmol), and 1-(3-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example G-1, 0.19 g, 0.48 mmol) provided 0.209 g of the title compound as a solid.

Example A-2

1-(3-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione

25 Using General Method 4, the reaction of 3-t-butoxycarbonylamino-pyrrolidine (0.266 g, 1.43 mmol), triethylamine (0.2 mL, 1.43 mmol), and 1-(3-fluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example G-1, 0.19 g, 0.48 mmol) provided 0.231 g of the title compound as a solid.

-59-

Example B-2

1-(2,4,5-Trifluorophenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione

5 Using General Method 4, the reaction of 3-t-butoxycarbonylamino-pyrrolidine (0.231 g, 1.24 mmol), triethylamine (0.178 mL, 1.24 mmol), and 1-(2,4,5-trifluorophenyl)-3-benzyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example H-1, 0.18 g, 0.41 mmol) provided 0.13 g of the title compound as a solid.

Example C-2

10 Ethyl 2-chloro-5-fluoro-6-pyrrolidinyl-3-pyridinecarboxylate

To a solution of ethyl 2,6-dichloro-5-fluoro-3-pyridinecarboxylate (3.00 g, 12.6 mmol; *J. Med. Chem.*, 1986:29:2363) and triethylamine (2.63 mL, 18.90 mmol) in acetonitrile (15 mL) was added pyrrolidine (1.05 mL, 12.6 mmol) dropwise. After being stirred at 60°C for 1 hour, the reaction mixture was
15 evaporated, and the residue was dissolved in dichloromethane, washed with water, and dried over anhydrous sodium sulfate. The residue was purified on a silica gel column using hexane/dichloromethane (7:3) as eluent giving 2.5 g of the title compound as a solid, mp 95°C.

Example D-2

20 Ethyl 2-chloro-5-fluoro-6-(4-methylpiperazinyl)-3-pyridinecarboxylate

Following the procedure of Example C-2, the reaction of 2,6-dichloro-5-fluoro-3-pyridinecarboxylate (2.00 g, 8.4 mmol) with 4-methylpiperazine (0.95 mL, 8.4 mmol) in acetonitrile (10 mL) in the presence of triethylamine (1.75 mL, 12.58 mmol) gave 2.34 g of the title compound as an oil.

25 Example E-2

Ethyl 2-cyclopropylamino-5-fluoro-6-pyrrolidinyl-3-pyridinecarboxylate

A solution of ethyl 2-chloro-5-fluoro-6-pyrrolidinyl-3-pyridinecarboxylate (Example C-2, 500 mg, 1.83 mmol) and cyclopropylamine (2 mL) in DMA (1 mL) was sealed in a pressure bottle and heated at 90°C for 1 day. The reaction
30 mixture was diluted with dichloromethane (40 mL), washed with water, and dried

-60-

on sodium sulfate. Flash chromatography on a silica gel column using dichloromethane/hexane (3:2) as eluent provided 270 mg of the title compound as an oil.

Example F-2

5 Ethyl 2-cyclopropylamino-5-fluoro-6-(4-methylpiperazinyl)-3-pyridinecarboxylate

10 A solution of ethyl 2-chloro-5-fluoro-6-(4-methylpiperazinyl)-3-pyridine-carboxylate (Example D-2, 1.00 g, 3.314 mmol) and cyclopropylamine (2 mL) in DMA (1 mL) was sealed in a pressure bottle and heated at 90°C for 60 hours. The reaction mixture was diluted with dichloromethane (30 mL), washed with water, and dried on sodium sulfate. Flash chromatography on silica gel column using dichloromethane as eluent provided compound 0.85 g of the title compound as an oil.

Example G-2

15 2-Cyclopropylamino-5-fluoro-6-pyrrolidinyl-3-pyridinecarboxylic acid

20 A solution of ethyl 2-cyclopropylamino-5-fluoro-6-pyrrolidinyl-3-pyridine-carboxylate (Example E-2, 270 mg, 0.92 mmol) and NaOH (360 mg, 9.0 mmol) in water (1 mL), THF (2 mL), and MeOH (1 mL) was refluxed for 3 hours. The mixture was cooled to room temperature, acidified with dilute HCl to pH 6, and evaporated under reduced pressure. The residue was mixed with 10% MeOH/dichloromethane (40 mL), dried on sodium sulfate, filtered, and evaporated. The solid residue was further washed with hexane and dried in vacuo, giving 215 mg of the title compound as powder, mp 64-66°C.

Example H-2

25 2-Cyclopropylamino-5-fluoro-6-(4-methylpiperazinyl)-3-pyridinecarboxylic acid

Following the procedure of Example G-2, the reaction of ethyl 2-cyclopropylamino-5-fluoro-6-(4-methylpiperazinyl)-3-pyridinecarboxylate (Example F-2, 0.86 g, 2.67 mmol) with NaOH (1.40 g, 35 mmol) in THF (5 mL) and water (2 mL) provided 0.50 g of the title compound as a foam.

-61-

Example I-2

N-Benzyloxy-2-cyclopropylamino-5-fluoro-6-pyrrolidinyl-3-pyridinecarboxamide

To a solution of 2-cyclopropylamino-5-fluoro-6-pyrrolidinyl-3-pyridinecarboxylic acid (Example G-2, 215 mg, 0.80 mmol) and
5 1-hydroxybenzotriazole (HOBT) (119 mg, 0.88 mmol) in chloroform (10 mL) was added 1-ethyl-3-(3'-dimethylamino-propyl)carbodiimide (EDCI) (169 mg, 0.88 mmol). After being stirred at room temperature for 30 minutes, O-benzylhydroxylamine hydrochloride (141 mg, 0.88 mmol) and triethylamine (0.122 mL, 0.88 mmol) were added. The reaction mixture was heated to reflux for
10 4 hours, diluted with dichloromethane, washed with water, and dried on sodium sulfate. The residue was purified by flash chromatography on a silica gel column with dichloromethane as eluent giving 155 mg of the title compound as an oil.

Example J-2

15 N-Benzyloxy-2-cyclopropylamino-5-fluoro-6-(4-methylpiperazinyl)-3-pyridinecarboxamide

Following the procedure of Example I-2, the reaction of 2-cyclopropylamino-5-fluoro-6-(4-methylpiperazinyl)-3-pyridinecarboxylic acid (Example H-2, 200 mg, 0.67 mmol) and HOBT (99.5 mg, 0.74 mmol) with EDCI (154.6 mg, 0.81 mmol) in dichloromethane (10 mL) followed by adding
20 O-benzylhydroxylamine hydrochloride (0.81 mmol) and triethylamine (0.113 mL, 0.81 mmol) gave a crude oil. Purification of the oil by flash chromatography on a silica gel column with 5% of MeOH in dichloromethane provided 160 mg of the title compound as an oil.

Example K-2

25 3-Benzyloxy-1-cyclopropyl-6-fluoro-7-pyrrolidinyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

A solution of N-benzyloxy-2-cyclopropylamino-5-fluoro-6-pyrrolidinyl-3-pyridinecarboxamide (Example I-2, 155 mg, 0.44 mmol) and 1,1'-carbonyldiimidazole (CDI) (142 mg, 0.88 mmol) in chloroform (2 mL) was
30 refluxed overnight. The mixture was concentrated and purified by flash

-62-

chromatography on a silica gel column with dichloromethane as eluent giving 130 mg of the title compound as a solid, mp 184-186°C.

Example L-2

3-Benzyloxy-1-cyclopropyl-6-fluoro-7-(4-methylpiperazinyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Following the procedure of Example K-2, the reaction of N-benzyloxy-2-cyclopropylamino-5-fluoro-6-(4-methylpiperazinyl)-3-pyridinecarboxamide (Example J-2, 160 mg, 0.42 mmol) with CDI (135 mg, 0.83 mmol) in chloroform (2 mL) and purification of the reaction mixture by flash chromatography on a silica gel with 5% of MeOH/dichloromethane as eluent provided 125 mg of the title compound as powder, mp 188-189°C.

Example M-2

N-Benzyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide

To a suspension of 2,6-dichloro-5-fluoro-3-pyridinecarboxylic acid (20.00 g, 95.2 mmol) and a few drops of DMF in dichloromethane (200 mL) was added oxalyl chloride (24.6 mL, 0.282 mol) dropwise. The mixture was stirred at room temperature until evolution of gas ceased, and the reaction mixture was evaporated under reduced pressure to remove excess of the reagent. The residue was dissolved in dichloromethane (200 mL) and O-benzylhydroxylamine hydrochloride (16.71 g, 0.105 mol) in dichloromethane (200 mL) and triethylamine (15.90 mL, 0.114 mmol) were added dropwise at 0°C. The mixture was stirred at room temperature for 3 hours, diluted with ethyl acetate (100 mL), washed with saturated aqueous sodium hydrogen carbonate, water, and dried on sodium sulfate. The solid residue was recrystallized from chloroform to give 14.87 g of the title compound as solid, mp 176-177°C.

General Method 5. A procedure for the synthesis of 1-substituted-3-benzyloxy-7-chloro-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione

To a solution of N-benzyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) in anhydrous dimethylacetamide (DMA) (25 mL) was added 60% NaH in oil (300 mg,

-63-

7.52 mmol). After bubbling of hydrogen ceased, an alkyl or aryl isocyanate (1.5-4.0 equiv.) was added, and the reaction mixture was stirred at room temperature for 1 to 10 hours and quenched with water (200 mL). The solid precipitate was collected by filtration, dissolved in dichloromethane, washed with water, and dried on sodium sulfate. Concentration of the organic layers often gave additional solid product, which were further washed with 20% of dichloromethane/hexane or recrystallized from chloroform.

Example N-2

3-Benzyl-7-chloro-1-ethyl-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzyl-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (380 mg, 9.52 mmol) with ethyl isocyanate (2.0 mL, 25.36 mmol) in DMA afforded 1.725 g of the title compound as a solid, mp 156-157°C.

Example O-2

3-Benzyl-1-butyl-7-chloro-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzyl-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with n-butyl isocyanate (2.14 mL, 19.02 mmol) in DMA afforded crude product. Recrystallization from chloroform provided 1.40 g of the title compound as a solid, mp 147-148°C.

Example P-2

1-Benzyl-3-benzyl-7-chloro-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzyl-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with benzyl isocyanate (1.17 mL, 9.51 mmol) in DMA afforded crude product. Recrystallization from chloroform provided 2.15 g of the title compound as a solid, mp 209-210°C.

-64-

Example Q-2

3-Benzoyloxy-7-chloro-6-fluoro-1-(4-fluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzoyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with 4-fluorophenyl isocyanate (0.86 mL, 9.51 mmol) in DMA afforded 1.89 g of the title compound as a solid, mp 208-209°C.

Example R-2

10 3-Benzoyloxy-7-chloro-6-fluoro-1-(2-fluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzoyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with 2-fluorophenyl isocyanate (1.07 mL, 9.51 mmol) in DMA afforded 2.05 g of the title compound as a solid, mp 199-200°C.

Example S-2

20 3-Benzoyloxy-7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzoyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with 2,4-difluorophenyl isocyanate (1.13 mL, 9.51 mmol) in DMA afforded 2.28 g of the title compound as a solid, mp 215-216°C.

25 Example T-2

3-Benzoyloxy-7-chloro-6-fluoro-1-(4-methylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzoyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with 4-methylphenyl isocyanate (1.20 mL,

-65-

9.51 mmol) in DMA afforded crude product. Recrystallization from chloroform provided 1.91 g of the title compound as a solid, mp 218-219°C.

Example U-2

3-Benzyloxy-7-chloro-6-fluoro-1-(4-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with 4-trifluoromethylphenyl isocyanate (1.36 mL, 9.51 mmol) in DMA afforded 1.97 g of the title compound as a solid, mp 245-246°C.

Example V-2

3-Benzyloxy-7-chloro-6-fluoro-1-(3-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with 3-trifluoromethylphenyl isocyanate (1.31 mL, 9.51 mmol) in DMA afforded 2.04 g of the title compound as a solid, mp 207-208°C.

Example W-2

3-Benzyloxy-7-chloro-6-fluoro-1-(4-methoxyphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the General Method 5, the reaction of N-benzyloxy-2,6-dichloro-5-fluoro-3-pyridinecarboxamide (Example M-2, 2.00 g, 6.34 mmol) and 60% NaH in oil (300 mg, 7.52 mmol) with 4-methoxyphenyl isocyanate (1.31 mL, 9.51 mmol) in DMA afforded crude product. Recrystallization from chloroform provided 1.85 g of the title compound as a solid, mp 238-240°C.

-66-

Example X-2

3-Benzoyloxy-1-ethyl-6-fluoro-7-pyrrolidinyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

To a solution of 3-benzyloxy-7-chloro-1-ethyl-6-fluoro-1H-pyrido[2,3-d]-
pyrimidine-2,4-dione (Example N-2, 146 mg, 0.42 mmol) in dichloromethane
(3 mL) was added pyrrolidine (0.070 mL, 0.84 mmol) and the mixture was stirred
at room temperature for 10 minutes. The reaction was diluted with
dichloromethane (10 mL). The organic phase was washed with saturated aqueous
sodium bicarbonate, dried on MgSO₄, and concentrated. Washing the solid
residue with hexane afforded 120 mg of the title compound as a solid,
mp 189-190°C.

Example Y-2

3-Benzoyloxy-1-ethyl-6-fluoro-7-(4-methylpiperazinyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Following the procedure of Example X-2, the reaction of 3-benzyloxy-
7-chloro-1-ethyl-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example N-2,
200 mg, 0.572 mmol) with 4-methylpiperazine (0.152 mL, 1.37 mmol) in
dichloromethane (3 mL) afforded 200 mg of the title compound as a solid,
mp 178-179°C.

Example Z-2

3-Benzoyloxy-1-ethyl-6-fluoro-7-[3-(N-*tert*-butoxycarbonylamino)pyrrolidin-1-yl]-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Following the procedure of Example X-2, the reaction of 3-benzyloxy-
7-chloro-1-ethyl-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example N-2,
200 mg, 0.572 mmol) with 3-(N-*tert*-butoxycarbonylamino)pyrrolidine (117 mg,
0.629 mmol) in dichloromethane (5 mL) in the presence of triethylamine
(0.087 mL) afforded 245 mg of the title compound as a solid, mp 157-159°C.

-67-

Example A-3

1-Benzyl-3-benzyloxy-6-fluoro-7-pyrrolidinyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

5 Following the procedure of Example X-2, the reaction of 1-benzyl-3-benzyloxy-7-chloro-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example P-2, 142 mg, 0.345 mmol) with pyrrolidine (0.070 mL, 0.828 mmol) in dichloromethane (3 mL) afforded 121 mg of the title compound as a solid, mp 171-172°C.

Example B-3

10 4-Chloro-2-cyclopropylamino-5-fluoro-benzoic acid, ethyl ester

 A mixture of 4-chloro-2,5-difluorobenzoic acid (5.0 g, 26 mmol) and dichloromethane (150 mL) was reacted with oxalyl chloride (6.0 mL, 69 mmol) and one drop of DMF. The mixture was stirred for 1.5 hours, then concentrated. The residue was then dissolved in dichloromethane (200 mL) and reacted with
15 ethanol (40 mL). After 30 minutes, the mixture was diluted with diethyl ether and washed with 1.0 N NaOH. The organic layer was then dried with sodium sulfate and the solvent concentrated. The residue was then taken up in acetonitrile (40 mL) and heated with an excess of cyclopropyl amine (20 mL) for 48 hours at 80°C. The mixture was cooled to ambient temperature and the solvent
20 concentrated. The residue was then taken up in diethyl ether and washed with water. The organic layer was dried with sodium sulfate and concentrated. The resulting residue was purified by column chromatography (silica gel, gradient dilution of hexanes to 20% ethyl acetate/hexanes) to provide a 4.16 g of the title compound as a solid.

25 Example C-3

4-Chloro-2-cyclopropylamino-5-fluoro-benzoic acid

 A solution of 4-chloro-2-cyclopropylamino-5-fluoro-benzoic acid ethyl ester (Example B-3, 4.10 g, 15.9 mmol) in THF (100 mL) was reacted with an aqueous solution of 1.0 N LiOH (45 mL, 45 mmol) and methanol (40 mL) and
30 allowed to stir overnight. The mixture was then concentrated to one-third volume and acidified with 1.0 N HCl. The mixture was extracted with ethyl acetate. the

-68-

organic layers combined, dried with sodium sulfate, and concentrated to provide 3.0 g of the title compound as an oil.

Example D-3

N-Benzyloxy-4-chloro-2-cyclopropylamino-5-fluoro-benzamide

5 Following the procedure of Example A, 4-chloro-2-cyclopropylamino-5-fluoro-benzoic acid (Example C-3, 2.0 g, 8.7 mmol) was reacted with carbonyldiimidazole (1.7 g, 10.5 mmol), O-benzylhydroxylamine hydrochloride (1.67 g, 10.5 mmol), and triethylamine (1.5 mL, 10.5 mmol) in THF (50 mL) to give 2.92 g of the title compound.

10

Example E-3

3-Benzyloxy-7-chloro-1-cyclopropyl-6-fluoro-1H-quinazoline-2,4-dione

 A solution of N-benzyloxy-4-chloro-2-cyclopropylamino-5-fluoro-benzamide (Example D-3, 3.00 g, 8.96 mmol) in 1,4-dioxane (50 mL) was reacted with a 20% solution of phosgene (7.00 mL, 9.86 mmol) in toluene in a sealed
15 tube. The mixture was heated to reflux for 24 hours, then cooled and quenched with H₂O. The mixture was extracted three times with ethyl acetate, the organic layers combined, dried with sodium sulfate, and concentrated. The residue was then purified by column chromatography (silica gel, 1:1 hexanes/ethyl acetate) to provide 1.5 g of the title compound as a solid.

20

Example F-3

3-Benzyloxy-1-cyclopropyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

 A solution of 3-benzyloxy-7-chloro-1-cyclopropyl-6-fluoro-1H-quinazoline-2,4-dione (Example E-3, 0.15 g, 0.42 mmol) in DMF (4.0 mL) was reacted with pyrrolidine (1.0 mL) and heated to 70°C overnight. The mixture was
25 then cooled, diluted with 0.25 M HCl, and extracted with ethyl acetate. The organic layers were combined, dried with sodium sulfate, and concentrated. The residue was then purified by column chromatography (silica gel, 1:1 hexanes/ethyl acetate) to provide 0.15 g of the title compound as a solid.

-69-

Example G-3

[1-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester

5 A solution of 3-benzoyloxy-7-chloro-1-cyclopropyl-6-fluoro-1H-quinazoline-2,4-dione (Example E-3, 0.15 g, 0.42 mmol) in DMF (3.0 mL) was reacted with pyrrolidin-3-yl-carbamic acid tert-butyl ester (0.700 g, 3.5 mmol) and triethylamine (0.70 mL, 5.0 mmol) then heated to 70°C overnight. The mixture was then cooled, diluted with H₂O, and extracted with ethyl acetate. The organic layers were combined, dried with sodium sulfate, and concentrated. The residue
10 was then purified by column chromatography (silica gel, 1:1 hexanes/ethyl acetate) to provide 0.10 g of the title compound as a solid.

Example H-3

[1-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl-methyl]-carbamic acid tert-butyl ester

15 A solution of 3-benzoyloxy-7-chloro-1-cyclopropyl-6-fluoro-1H-quinazoline-2,4-dione (Example E-3, 0.162 g, 0.44 mmol) in DMF (3.0 mL) was reacted with pyrrolidin-3-yl-methyl-carbamic acid tert-butyl ester (0.40 g, 2.0 mmol) and triethylamine (0.63 mL, 4.5 mmol) then heated to 70°C for 2 days. The mixture was then cooled, diluted with H₂O, and extracted with ethyl acetate.
20 The organic layers were combined, dried with sodium sulfate, and concentrated. The residue was then purified by column chromatography (silica gel, 1:1 hexanes/ethyl acetate) to provide 0.127 g of the title compound as a solid.

Example I-3

[1-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-azetidin-3-yl]-carbamic acid tert-butyl ester

25 A solution of 3-benzoyloxy-7-chloro-1-cyclopropyl-6-fluoro-1H-quinazoline-2,4-dione (Example E-3, 0.20 g, 0.55 mmol) in DMA (3.0 mL) was reacted with azetidin-3-yl-carbamic acid tert-butyl ester (0.286 g, 1.66 mmol), triethylamine (0.76 mL, 5.5 mmol) and heated to 80°C for 2 days. The mixture
30 was then cooled, diluted with H₂O, and extracted with ethyl acetate. The organic

-70-

layers were combined, dried with sodium sulfate, and concentrated. The residue was purified by column chromatography (silica gel, 3:1 hexanes/ethyl acetate to 1:1 hexanes/ethyl acetate) to provide 0.13 g of the title compound as a solid.

Example J-3

5 (1 α ,5 α ,6 α)[3-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-
quinazolin-7-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester

A solution of 3-benzyloxy-7-chloro-1-cyclopropyl-6-fluoro-1H-quinazoline-2,4-dione (Example E-3, 0.20 g, 0.55 mmol) in DMSO (3.0 mL) was reacted with 3-aza-bicyclo[3.1.0]hex-6-yl-carbamic acid tert-butyl ester (0.22 g, 1.1 mmol) and triethylamine (0.76 mL, 5.5 mmol), then heated to 100°C for 2 days. The mixture was cooled, diluted with H₂O, and extracted with ethyl acetate. The organic layers were combined, washed with saturated aqueous LiCl, dried with sodium sulfate, and concentrated. The residue was purified by column chromatography (silica gel, 1:1 hexanes/ethyl acetate) to provide 0.195 g of the title compound as a solid.

10
15

Example K-3

[4 α R-(4 $\alpha\alpha$,7 $\alpha\alpha$)]6-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-
1,2,3,4-tetrahydro-quinazolin-7-yl)-octahydro-pyrrolo[3.4-b]pyridine-1-carboxylic
acid tert-butyl ester

20 A solution of 3-benzyloxy-7-chloro-1-cyclopropyl-6-fluoro-1H-quinazoline-2,4-dione (Example E-3, 0.16 g, 0.44 mmol) in DMSO (3.0 mL) was reacted with octahydro-pyrrolo[3.4-b]pyridine-1-carboxylic acid tert-butyl ester (0.402 g, 1.8 mmol), triethylamine (0.28 mL, 2.0 mmol) and heated to 100°C for 3 days. The mixture was then cooled, diluted with H₂O, and extracted with ethyl acetate. The organic layers were combined, washed with saturated aqueous LiCl, dried with sodium sulfate, and concentrated. The residue was purified by column chromatography (silica gel, 1:1 hexanes/ethyl acetate) to provide 0.22 g of the title compound as an oil.

25

-71-

Example L-3

7,8-Difluoro-4H-benzo[1,4]thiazin-3-one

A solution of 1,2,3-trifluoro-4-nitrobenzene (6.0 g, 34 mmol) in ethanol (15 mL) was reacted with methylthioglycolate (3.66 mL, 40.7 mmol) and NaHCO₃ (3.42 g, 40.7 mmol) and the mixture heated to reflux for 4 hours. The mixture was then cooled, diluted with ethyl acetate, and washed with 1.0N NaOH. The organic layer was then dried with sodium sulfate and the solvent concentrated. The residue was purified by column chromatography (silica gel, 1:1 hexanes/dichloromethane) to provide a solid (5.89 g) as a mixture of isomers, which was taken up in acetic acid (90 mL) and ethanol (50 mL) in a 3-necked flask equipped with a mechanical stirrer. The mixture was reacted with reduced iron powder (5.0 g) and the mixture heated to reflux (N₂ atmosphere) for 5 hours and cooled. The mixture was concentrated, taken up with ethyl acetate, and subsequently filtered. The filtrate was washed with saturated NaHCO₃, the organic layer dried with sodium sulfate and concentrated to provide 2.4 g of the title compound as a solid.

¹H NMR (300 MHz, DMSO-*d*₆) δ 3.53 (s, 2H), 6.75-6.80 (m, 1H), 7.26 (q, 1H, J = 9 Hz), 10.76 (bs, 1H).

Example M-3

7,8-Difluoro-3,4-dihydro-2H-benzo[1,4]thiazine

A solution of 7,8-difluoro-4H-benzo[1,4]thiazin-3-one (Example L-3, 2.27 g, 11.3 mmol) in THF (100 mL) was reacted with lithium aluminumhydride (1.07 g, 28.2 mmol) under an N₂ atmosphere and heated to reflux overnight. The mixture was cooled and quenched with 1.0N HCl and extracted with ethyl acetate. The organic layers were combined, dried with sodium sulfate, and concentrated to provide 2.2 g of the title compound as an oil.

Example N-3

6,7-Difluoro-3,4-dihydro-5-thia-2α-aza-acenaphthylene-1,2-dione

A solution of chloral hydrate (2.22 g, 13.3 mmol), sodium sulfate 10 H₂O (86.0 g, 267 mmol), and hydroxylamine hydrochloride (2.78 g, 40.1 mmol) in

-72-

H₂O (200 mL) was reacted with a mixture of 7,8-difluoro-3,4-dihydro-2H-benzo[1,4]thiazine (Example M-3, 2.20 g, 13.4 mmol), 1.0 M aqueous HCl (13.4 mL), and methanol (5.0 mL). The reaction was heated to 100°C overnight. The mixture was cooled, extracted with ethyl acetate, the organic layers combined, dried with sodium sulfate, and concentrated. The residue was reacted with concentrated H₂SO₄ (20 mL) and heated to 50°C for 30 minutes. The mixture was quenched with H₂O and extracted with ethyl acetate. The organic layers were combined, dried with sodium sulfate and concentrated to provide 2.05 g of the title compound as an oil.

10

Example O-3

5-Benzyloxy-8,9-difluoro-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione

6,7-Difluoro-3,4-dihydro-5-thia-2 α -aza-acenaphthylene-1,2-dione (Example N-3, 2.05 g) was dissolved in methanol (150 mL), reacted with a 1.0 M aqueous solution of NaOH (36 mL), cooled to 0°C, and reacted with 30% H₂O₂ (2.8 mL, 34 mmol). The mixture was stirred for 1.5 hours, then quenched with an excess of Na₂S₂O₃ and allowed to stir for 20 minutes acidified with a 1.0 N solution of HCl. The mixture was extracted with ethyl acetate, the organic layer dried with sodium sulfate, and concentrated. The residue was dissolved in diethyl ether and extracted with 1.0N aqueous NaOH. The aqueous layers were combined, acidified with concentrated HCl, and the mixture extracted with ethyl acetate three times. The organic layers were combined, dried with sodium sulfate, and concentrated. The residue (1.7 g) was then dissolved in THF (40 mL) and reacted with carbonyldiimidazole (1.49 g, 9.19 mmol). The mixture was heated to 60°C (N₂ atmosphere) for 4 hours and subsequently cooled and reacted with O-benzylhydroxylamine hydrochloride (2.93 g, 18.4 mmol) and triethylamine (2.56 mL, 18.4 mmol). The mixture was then heated to reflux overnight, cooled, and diluted with 0.5 N HCl. The product was extracted with ethyl acetate, the organic layers combined, dried with sodium sulfate, and concentrated. The residue was suspended in THF (100 mL) and reacted with carbonyldiimidazole. The mixture was refluxed for 3 days, cooled, concentrated under reduced pressure,

-73-

diluted with 1.0 N HCl, and extracted with ethyl acetate. The organic layers were combined, diluted with methanol, dried with sodium sulfate, and concentrated. The resulting solid was washed with a 1:1 mixture of diethyl ether/hexanes to provide 1.91 g of the title compound.

5 ^1H NMR (300 MHz, CDCl_3) δ 3.20-3.40 (m, 2H, partially obscured by H_2O), 4.29-4.32 (m, 2H), 5.12 (s, 2H), 7.37-7.45 (m, 3H), 7.55-7.58 (m, 2H), 7.83 (t, 1H, $J = 9$ Hz).

Example P-3

10 5-Benzyloxy-8-fluoro-9-pyrrolidin-1-yl-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione

A solution of 5-benzyloxy-8,9-difluoro-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione (Example O-3, 0.150 g, 0.41 mmol) in DMF (3.0 mL) was reacted with pyrrolidine (0.105 mL, 1.23 mmol) and triethylamine (0.17 mL, 1.23 mmol), and then heated to 50°C overnight. The mixture was cooled, diluted with H_2O , and extracted with ethyl acetate. The organic layers were combined, dried with sodium sulfate, and concentrated. The residue was then purified by column chromatography (silica gel, 7:3 hexanes/ethyl acetate) to provide 0.13 g of the title compound as a solid.

Example Q-3

20 [1-(5-Benzyloxy-8-fluoro-4,6-dioxo-2,3,5,6-tetrahydro-4H-1-thia-3 α ,5-diaza-phenalen-9-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester

25 A solution of 5-benzyloxy-8,9-difluoro-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione (Example O-3, 0.200 g, 0.55 mmol) in DMF (3.0 mL) was reacted with pyrrolidin-3-yl-carbamic acid tert-butyl ester (0.30 g, 1.66 mmol) and triethylamine (0.38 mL, 2.75 mmol) and then heated to 50°C overnight. The mixture was then cooled, diluted with H_2O , and extracted with ethyl acetate. The organic layers were combined, dried with sodium sulfate, and concentrated. The residue was purified by column chromatography (silica gel, 6:4 hexanes/ethyl acetate) to provide 0.185 g of the title compound as a solid.

-74-

Example R-3

(1 α ,5 α ,6 α)[3-(5-Benzoyloxy-8-fluoro-4,6-dioxo-2,3,5,6-tetrahydro-4H-1-thia-3 α ,5-diaza-phenalen-9-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester

5 A solution of 5-benzyloxy-8,9-difluoro-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione (Example O-3, 0.25 g, 0.69 mmol) in DMSO (3.0 mL) was reacted with 3-aza-bicyclo[3.1.0]hex-6-yl-carbamic acid tert-butyl ester (0.21 g, 1.04 mmol) and triethylamine (0.21 mL, 5.0 mmol) and then heated to 50°C overnight. The mixture was cooled, diluted with ethyl acetate, and washed with
10 H₂O and saturated aqueous LiCl. The organic layers were combined, dried with sodium sulfate, and concentrated. The residue was purified by column chromatography (silica gel, 1:1 hexanes/ethyl acetate) to provide 0.204 g of the title compound as a solid.

Example S-3

15 2,3,5-Trifluoro-4-pyrrolidin-1-yl-benzoic acid ethyl ester

 A solution of 2,3,4,5-tetrafluorobenzoic acid (5.0 g, 28.7 mmol) in dichloromethane (20 mL) was reacted with oxalyl chloride (7.5 mL, 86.1 mmol) and one drop of DMF. The mixture was stirred for 30 minutes and concentrated. The residue was dissolved in dichloromethane (20 mL) and reacted with an excess
20 of dry ethanol. After 10 minutes, H₂O was added and the mixture extracted with diethyl ether. The organic layer was then dried with sodium sulfate and concentrated. The residue was taken up in acetonitrile (100 mL) and reacted with triethylamine (21.0 mL, 150 mmol) and pyrrolidine (3.2 mL, 37 mmol). The reaction was allowed to proceed overnight and was concentrated. The residue was
25 taken up in diethyl ether and washed with saturated NaHCO₃. The organic layer was dried with magnesium sulfate and concentrated to provide 4.8 g of the title compound as an oil.

-75-

Example T-3

2-Cyclopropylamino-3,5-difluoro-4-pyrrolidin-1-yl-benzoic acid

A solution of 2,3,5-trifluoro-4-pyrrolidin-1-yl-benzoic acid ethyl ester (Example S-3, 2.4 g, 8.79 mmol) in DMSO (10 mL) was reacted with
5 cyclopropylamine (10 mL) and the mixture heated to 110°C for 2 days in a sealed tube. The mixture was cooled and diluted with H₂O, acidified with citric acid, and extracted with ethyl acetate. The organic layers were combined, dried with magnesium sulfate, and concentrated to provide an oil (2.7 g). The residue was taken up in methanol (20 mL) and reacted with lithium hydroxide (1.05 g,
10 44.0 mmol) in H₂O (20 mL) and THF (20 mL). The mixture was allowed to stir for 5 days, then acidified with citric acid. The mixture was extracted with ethyl acetate, the organic layers combined, dried with sodium sulfate, and concentrated. The residue was filtered through a plug of silica gel with chloroform to provide 1.65 g of the title compound as a solid.

15 Example U-3

3-tert-Butoxy-1-cyclopropyl-6,8-difluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

A solution of 2-cyclopropylamino-3,5-difluoro-4-pyrrolidin-1-yl-benzoic acid (Example T-3, 1.65 g, 5.85 mmol) in THF (20 mL) was reacted with
20 carbonyldiimidazole (1.2 g, 7.31 mmol) and stirred overnight at ambient temperature. The mixture was reacted with triethylamine (1.22 mL, 8.77 mmol) and O-t-butyl hydroxylamine hydrochloride (1.10 g, 8.77 mmol) and allowed to stir for 4 hours. The mixture was quenched with H₂O and extracted with ethyl acetate. The organic layers were combined, dried with sodium sulfate, and
25 concentrated. The resulting residue was dissolved in THF (15 mL), reacted with carbonyldiimidazole (2.44 g, 15.0 mmol), and heated to 100°C in a sealed tube for 5 days. The mixture was cooled, diluted with H₂O, and extracted with ethyl acetate. The organic layer was washed with H₂O, dried with sodium sulfate, and concentrated. The residue was purified by column chromatography (silica gel,
30 1:1 hexanes/ethyl acetate) to provide 0.52 g of the title compound as a solid.

-76-

¹H NMR (300 MHz, DMSO-*d*₆) δ 0.62 (bs, 1H), 0.80 (bs, 1H), 0.98 (bs, 2H), 1.24 (s, 9H), 1.87 (bs, 4H), 3.16-3.19 (m, 1H), 3.59 (bs, 4H), 7.35 (dd, 1H, J = 2 Hz, J = 13 Hz).

Example V-3

5 2-Amino-N-benzyloxy-3,4,5,6-tetrafluoro-benzamide

Following the procedure for Example A, 2-amino-3,4,5,6-tetrafluorobenzoic acid (3.0 g, 14.4 mmol) was reacted with carbonyldiimidazole (2.8 g, 17.2 mmol), O-benzylhydroxylamine hydrochloride (3.44 g, 21.5 mmol), and triethylamine (3.0 mL, 21.5 mmol) in THF (50 mL) to provide 4.8 g of the
10 title compound.

Example W-3

3-Benzyloxy-5,6,7,8-tetrafluoro-1H-quinazoline-2,4-dione

A solution of 2-amino-N-benzyloxy-3,4,5,6-tetrafluoro-benzamide (Example V-3, 1.72 g, 5.47 mmol) in 1,4-dioxane (50 mL) was reacted with a
15 20% solution of phosgene (4.25 mL, 8.00 mmol) in toluene and heated to 80°C in a sealed tube for 18 hours. The mixture was then cooled, diluted with ethyl acetate, and washed with saturated aqueous NaHCO₃. The organic layer was dried with magnesium sulfate and concentrated. The residue was triturated with diethyl ether and filtered to provide 0.95 g of the title compound as a solid.

20

Example X-3

3-Benzyloxy-1-ethyl-5,6,8-trifluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

A solution of 3-benzyloxy-5,6,7,8-tetrafluoro-1H-quinazoline-2,4-dione (Example W-3, 0.90 g, 2.7 mmol), in DMA (10 mL) was reacted with pyrrolidine (0.55 mL, 6.6 mmol) and heated to 60°C for 3 hours. The mixture was then cooled
25 and quenched with H₂O and acidified with citric acid. The mixture was then extracted with ethyl acetate, dried with MgSO₄, and concentrated. The residue was triturated with diethyl ether/hexanes and the solid filtered and dried (0.87 g). A portion of the solid (0.500 g, 1.28 mmol) was dissolved in DMF and reacted with ethyl iodide (1.0 mL, 12.77 mmol) and sodium hydride (0.060 g, 1.5 mmol).

-77-

The mixture was stirred for 16 hours. The mixture was quenched with H₂O and extracted with ethyl acetate. The organic layers were combined, dried with sodium sulfate, and concentrated. The residue was triturated with diethyl ether and filtered to yield 0.25 g of the title compound as a solid.

5 ¹H NMR (300 MHz, DMSO-*d*₆) δ 1.29 (t, 3H, J = 7 Hz), 1.83-1.90 (bm, 4H), 3.66 (bs, 4H), 4.00-4.10 (bm, 2H), 5.04 (s, 2H), 7.38-7.41 (m, 3H), 7.53-7.56 (m, 2H).

Example Y-3

2-Amino-N-allyloxy-4, 5-difluoro-benzamide

10 Carbonyldiimidazole (3.37 g, 20 mmol) was added to a suspension of 4,5-difluoroanthranilic acid (3.0 g, 17 mmol) in 80 mL of THF, and the mixture was heated to reflux for 2 hours. The solution was cooled and O-allylhydroxylamine hydrochloride (1.89 g, 17 mmol) and triethylamine (2.8 mL, 20 mmol) were added, and the mixture was heated to reflux for 17 hours.

15 The reaction mixture was concentrated and washed with 1N HCl, saturated NaHCO₃, and brine and dried over magnesium sulfate. The solution was concentrated and purified by column chromatography (silica gel, CHCl₃/MeOH, 98:2) to give 2.08 g of the title compound as a solid.

Example Z-3

3-Allyloxy-6,7-difluoro-1H-quinazoline-2,4-dione

20 Phosgene, as a 12.5% solution in toluene (9.4 mL, 12 mmol), was added to a solution of 2-amino-N-allyloxy-4,5-difluorobenzamide (Example Y-3, 2.08 g, 9.1 mmol) in 75 mL of dioxane. The solution was heated at reflux for 20 hours and then poured into 200 mL of water. The aqueous solution was extracted with

25 ethyl acetate, and the combined organic fractions were washed with water and brine and dried over magnesium sulfate. The solution was concentrated to give 2.18 g of the title compound as a solid, mp 220-221°C.

-78-

Example A-4

3-Allyloxy-1-benzyl-6,7-difluoro-1H-quinazoline-2,4-dione

A solution of 3-allyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example Z-3, 0.7 g, 2.8 mmol) in 20 mL of DMF was added to a suspension of sodium hydride (0.12 g, 3.0 mmol) in 15 mL of DMF and stirred for 30 minutes. Benzyl bromide (0.65 mL, 5.5 mmol) was added, and the mixture was stirred at 25°C for 18 hours. The reaction was quenched with 1 mL of water and concentrated to an oil. The residue was dissolved in chloroform washed with water and brine and dried over magnesium sulfate. The solution was concentrated to give 1.04 g of the title compound as a solid, mp 130-132°C.

Example B-4

3-Allyloxy-1-benzyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Pyrrolidine (0.04 mL, 0.52 mmol) was added to a solution of 3-allyloxy-1-benzyl-6,7-difluoro-1H-quinazoline-2,4-dione (Example A-4, 0.15 g, 0.4 mmol) and triethylamine (0.12 mL, 0.9 mmol) in 15 mL of acetonitrile. The solution was warmed to reflux for 17 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.15 g of the title compound as a solid, mp 148-150°C.

Example C-4

1-(3-Allyloxy-1-benzyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester

N-Boc-3-aminopyrrolidine (0.12 g, 0.65 mmol) was added to a solution of 3-allyloxy-1-benzyl-6,7-difluoro-1H-quinazoline-2,4-dione (Example A-4, 0.15 g, 0.4 mmol) and triethylamine (0.12 mL, 0.9 mmol) in 15 mL of acetonitrile. The solution was warmed to reflux for 17 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, saturated NaHCO₃, brine and dried over magnesium sulfate. The solution was concentrated to give 0.24 g of the title compound as a glass.

-79-

NMR (CDCl₃) δ 7.62 (d, 1H), 7.26 (m, 5H), 6.15 (m, 1H), 5.95 (d, 1H), 5.31 (dd, 2H), 5.22 (bs, 2H), 4.70 (d, 2H), 4.60 (bs, 1H), 4.21 (m, 1H), 3.60-3.18 (m, 4H), 2.11 (m, 1H), 1.83 (m, 1H), 1.38 (s, 9H).

Example D-4

5 3-Benzoyloxy-1-(2-fluoroethyl)-6,7-difluoro-1H-quinazoline-2,4-dione

A solution of 3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione (Example B, 1.0 g, 3.2 mmol) in 20 mL of DMF was added to a suspension of sodium hydride (0.16 g, 3.9 mmol) in 20 mL of DMF and stirred for 30 minutes. 2-Fluoroethyl iodide (1.1 g, 6.4 mmol) was added, and the mixture was warmed to 10 50°C for 18 hours. The reaction was quenched with 1 mL of water and concentrated to an oil. The residue was dissolved in chloroform, washed with water, brine and dried over magnesium sulfate. The solution was concentrated to give 0.73 g of the title compound as a solid, mp 145-147°C.

Example E-4

15 3-Benzoyloxy-1-(2-fluoroethyl)-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Pyrrolidine (0.04 mL, 0.52 mmol) was added to a solution of 3-benzoyloxy-1-(2-fluoroethyl)-6,7-difluoro-1H-quinazoline-2,4-dione (Example D-4, 0.15 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) in 20 mL of acetonitrile. The 20 solution was warmed to reflux for 17 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, saturated NaHCO₃, brine and dried over magnesium sulfate. The solution was concentrated to give 0.14 g of the title compound as a solid.

Example F-4

25 1-(3-Benzoyloxy-1-(2-fluoroethyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester

N-Boc-3-aminopyrrolidine (0.09 g, 0.65 mmol) was added to a solution of 3-benzoyloxy-1-(2-fluoroethyl)-6,7-difluoro-1H-quinazoline-2,4-dione (Example D-4, 0.15 g, 0.4 mmol) and triethylamine (0.36 mL, 2.6 mmol) in

-80-

20 mL of acetonitrile. The solution was warmed to reflux for 41 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, saturated NaHCO₃, brine and dried over magnesium sulfate. The solution was concentrated to give 0.20 g of the title compound as a solid.

5

Example G-4

3-Benzoyloxy-1-(2-fluoroethyl)-6-fluoro-7-(ethyl-pyrrolidin-3-ylmethyl-amine-1-yl)-1H-quinazoline-2,4-dione

Ethyl-pyrrolidin-3-ylmethyl-amine (0.06 g, 0.51 mmol) was added to a solution of 3-benzoyloxy-1-(2-fluoroethyl)-6,7-difluoro-1H-quinazoline-2,4-dione (Example D-4, 0.15 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) in 20 mL of acetonitrile. The solution was warmed to reflux for 17 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform, washed with brine, and dried over magnesium sulfate. The solution was concentrated to give 0.21 g of solid, which was purified by column chromatography (silica gel, CHCl₃/MeOH, 80:20) to give 0.13 g of the title compound as a solid.

15

Example H-4

2-(2,4-Difluoroanilino)-4,5-difluorobenzoic acid

Lithium diisopropylamide was generated at -5°C by combining diisopropylamine (7.2 mL, 51 mmol) and n-butyl lithium (33 mL, 53 mmol) in 150 mL of dry THF. After 30 minutes, the solution was cooled to -78°C and 2,4-difluoroaniline (3.46 mL, 34 mmol) was added and stirred for 2 hours. 2,4,5-Trifluorobenzoic acid (3.0 g, 17 mmol) was added, and the mixture was allowed to warm to room temperature over 17 hours. A saturated solution of HCl/dioxane (10 mL) was added, and after 1 hour the mixture was concentrated to a solid. The solid was redissolved in chloroform and washed with 1N HCl, water, and brine. The solution was dried and concentrated to afford 4.54 g of the title compound as a solid.

20

25

¹H NMR (CDCl₃) δ 8.95 (bs, 1H), 7.80 (m, 2H), 7.24 (m, 1H), 6.90 (m, 2H), 6.48 (m, 1H).

-81-

Example I-4

N-Benzyloxy-2-(2,4-difluoroanilino)-4,5-difluoro-benzamide

Carbonyldiimidazole (3.1 g, 19.1 mmol) was added to a suspension of 2-(2,4-difluoroanilino)-4,5-difluorobenzoic acid (Example H-4, 4.54 g, 15.9 mmol) in 120 mL of THF, and the mixture was stirred for 24 hours at 25°C. O-Benzyloxyhydroxylamine hydrochloride (2.54 g, 15.9 mmol) and triethylamine (2.66 mL, 19.1 mmol) were added, and the mixture was heated to reflux for 4 hours. The reaction mixture was concentrated and washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution was concentrated to give 5.66 g of the title compound as an oil.

Example J-4

3-Benzyloxy-1-(2,4-difluorophenyl)-6,7-difluoro-1H-quinazoline-2,4-dione

N-benzyloxy-2-(2,4-difluoroanilino)-4,5-difluoro-benzamide (Example I-4, 5.66 g, 15 mmol) and carbonyldiimidazole (2.83 g, 17 mmol) were combined in 300 mL of THF and heated to reflux for 30 hours. The solution was cooled, concentrated, and redissolved in chloroform. The solution was washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution was concentrated to give 4.25 g of a solid which was purified by column chromatography (silica gel, CHCl₃/MeOH, 98:2) to give 2.0 g of the title compound as a solid.

Example K-4

3-Benzyloxy-1-(2,4-difluorophenyl)-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Pyrrolidine (0.04 mL, 0.52 mmol) was added to a solution of 3-benzyloxy-1-(2,4-difluorophenyl)-6,7-difluoro-1H-quinazoline-2,4-dione (Example J-4, 0.20 g, 0.45 mmol) and triethylamine (0.34 mL, 2.4 mmol) in 20 mL of acetonitrile. The solution was warmed to reflux for 6 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform, washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.23 g of the title compound as a solid, mp 212-214°C.

-82-

Example L-4

1-(3-Benzyloxy-1-(2,4-difluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester

5 N-Boc-3-aminopyrrolidine (0.11 g, 0.57 mmol) was added to a solution of 3-benzyloxy-1-(2,4-difluorophenyl)-6,7-difluoro-1H-quinazoline-2,4-dione (Example J-4, 0.2 g, 0.43 mmol) and triethylamine (0.34 mL, 2.4 mmol) in 20 mL of acetonitrile. The solution was warmed to reflux for 41 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform, washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution
10 was concentrated to give 0.27 g of the title compound as a solid.

Example M-4

3-Benzyloxy-6,7-difluoro-1-cyclopropylmethyl-1H-quinazoline-2,4-dione

A solution of 3-benzyloxy-6,7-difluoro-1H-quinazoline-2, 4-dione (Example B, 1.22 g, 4 mmol) in 25 mL of DMF was added to a suspension of sodium hydride (0.19 g, 4.8 mmol) in 20 mL of DMF and stirred for 30 minutes.
15 Bromomethylcyclopropane (0.6 mL, 6.0 mmol) was added, and the mixture was stirred at 25°C for 18 hours. The reaction was quenched with 1 mL of water and concentrated to an oil. The residue was dissolved in chloroform, washed with water, brine, and dried over magnesium sulfate. The solution was concentrated to
20 give 1.10 g of the title compound as a solid, mp 121-123°C.

Example N-4

3-Benzyloxy-6-fluoro-1-(4-fluorophenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Pyrrolidine (0.04 mL, 0.52 mmol) was added to a solution of 3-benzyloxy-7-chloro-6-fluoro-1-(4-fluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example Q-2, 0.17 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) in 20 mL of acetonitrile. The solution was warmed to reflux for 17 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform, washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The
25 solution was concentrated to give 0.15 g of the title compound as a solid.
30

-83-

Example O-4

3-Benzoyloxy-1-butyl-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

5 Pyrrolidine (0.04 mL, 0.52 mmol) was added to a solution of 3-benzoyloxy-1-butyl-7-chloro-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example O-2, 0.16 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) in 20 mL of acetonitrile. The solution was warmed to reflux for 17 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, saturated NaHCO₃, brine, and dried over magnesium sulfate. The solution
10 was concentrated to give 0.14 g of the title compound as a solid.

Example P-4

3-Benzoyloxy-6-fluoro-7-pyrrolidin-1-yl-1-(4-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the method of Example N-4, pyrrolidine (0.04 mL, 0.52 mmol),
15 3-benzoyloxy-7-chloro-6-fluoro-1-(4-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example U-2, 0.19 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.18 g of the title compound as a solid, mp 231-233°C.

Example Q-4

20 3-Benzoyloxy-1-(2,4-difluorophenyl)-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the method of Example N-4, pyrrolidine (0.04 mL, 0.52 mmol),
3-benzoyloxy-7-chloro-6-fluoro-1-(2,4-difluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example S-2, 0.18 g, 0.42 mmol) and
25 triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.15 g of the title compound as a solid, mp 183-185°C.

-84-

Example R-4

3-Benzoyloxy-6-fluoro-1-(4-methylphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

5 Using the method of Example N-4, pyrrolidine (0.04 mL, 0.52 mmol), 3-benzoyloxy-7-chloro-6-fluoro-1-(4-methylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example T-2, 0.17 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.17 g of the title compound as a solid, mp 192-194°C.

Example S-4

10 3-Benzoyloxy-6-fluoro-7-pyrrolidin-1-yl-1-(3-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the method of Example N-4, pyrrolidine (0.04 mL, 0.52 mmol), 3-benzoyloxy-7-chloro-6-fluoro-1-(3-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example V-2, 0.19 g, 0.42 mmol) and
15 triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.16 g of the title compound as a solid, mp >250°C.

Example T-4

3-Benzoyloxy-6-fluoro-1-(2-fluorophenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

20 Using the method of Example N-4, pyrrolidine (0.04 mL, 0.52 mmol), 3-benzoyloxy-7-chloro-6-fluoro-1-(2-fluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example R-2, 0.15 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.16 g of the title compound as a solid, mp 221-222°C.

25 Example U-4

3-Benzoyloxy-6-fluoro-1-(4-methoxyphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the method of Example N-4, pyrrolidine (0.04 mL, 0.52 mmol), 3-benzoyloxy-7-chloro-6-fluoro-1-(4-methoxyphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example W-2, 0.17 g, 0.42 mmol) and
30

-85-

triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.17 g of the title compound as a solid, mp 186-188°C.

Example V-4

3-Benzoyloxy-1-cyclopropylmethyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Using the method of Example N-4, pyrrolidine (0.04 mL, 0.52 mmol), 3-benzoyloxy-6,7-difluoro-1-methylcyclopropyl-1H-quinazoline-2,4-dione (Example M-4, 0.15 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.16 g of the title compound as a solid, mp 198-200°C.

Example W-4

1-(3-Benzoyloxy-1-cyclopropylmethyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester

Using the method of Example N-4, boc-3-aminopyrrolidine (0.09 g, 0.52 mmol), 3-benzoyloxy-6,7-difluoro-1-methylcyclopropyl-1H-quinazoline-2,4-dione (Example M-4, 0.15 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.17 g of the title compound as a solid.

Example X-4

1-(3-Benzoyloxy-1-(4-fluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-pyrido[2,3-d]pyrimidine-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester

Using the method of Example N-4, boc-3-aminopyrrolidine (0.09 g, 0.52 mmol), 3-benzoyloxy-7-chloro-6-fluoro-1-(4-fluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example Q-2, 0.17 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.26 g of the title compound as a solid, mp 128-130°C.

-86-

Example Y-4

(1 α ,5 α ,6 α)[3-(3-Benzoyloxy-1-(4-fluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-pyrido[2,3-d]pyrimidine-7-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester

- 5 Using the method of Example N-4, 3-aza-bicyclo[3.1.0]hex-6-yl-carbamic acid tert-butyl ester (0.1 g, 0.52 mmol), 3-benzoyloxy-7-chloro-6-fluoro-1-(4-fluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example Q-2, 0.17 g, 0.42 mmol) and triethylamine (0.36 mL, 2.6 mmol) were combined in 20 mL of acetonitrile to give 0.25 g of the title compound as a solid, mp 244-245°C.

10

Example 1

1-Ethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

- Five percent Pd/BaSO₄ (60 mg) was added to a solution of 3-benzoyloxy-1-ethyl-6-fluoro-7-pyrrolidinyl-1H-quinazoline-2,4-dione (Example E, 0.21 g, 0.55 mmol) in 16 mL of THF. The mixture was shaken under 50 PSI of hydrogen for 31 hours, filtered, and concentrated to afford 0.16 g of a solid. This solid was dissolved in 1N sodium hydroxide and washed with chloroform. The chloroform layer was back extracted with sodium hydroxide, and the combined basic extracts were acidified to pH 3. The aqueous layer was extracted with chloroform, dried over magnesium sulfate, and concentrated to give 0.11 g of the title compound as a solid, mp 170-171°C.
- 15
- 20

Example 2

1-Ethyl-6-fluoro-3-hydroxy-7-(4-methyl-piperazin-1-yl)-1H-quinazoline-2,4-dione

- Five percent Pd/BaSO₄ (110 mg) was added to a solution of 3-benzoyloxy-1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione (Example H, 0.14 g, 0.33 mmol) in 50 mL of THF. The mixture was shaken under 50 PSI of hydrogen for 60 hours, filtered, and concentrated to afford 0.1 g of the title compound as a solid, mp 132-134°C.
- 25

-87-

Example 3

1-Ethyl-6-fluoro-3-hydroxy-7-morpholin-4-yl-1H-quinazoline-2,4-dione

Five percent Pd/BaSO₄ (50 mg) was added to a solution of 3-benzyloxy-1-ethyl-6-fluoro-7-morpholino-1H-quinazoline-2,4-dione (Example G, 0.23 g, 0.58 mmol) in 70 mL of THF and 5 mL methanol. The mixture was shaken under 50 PSI of hydrogen for 16 hours, filtered, and concentrated to afford 0.17 g of the title compound as a solid, mp 162-163°C.

Example 4

1-Ethyl-6-fluoro-3-hydroxy-7-piperidin-1-yl-1H-quinazoline-2,4-dione

Piperidine (0.025 mL, 0.22 mmol) was added to a solution of 1-ethyl-6,7-difluoro-3-hydroxy-1H-quinazoline-2,4-dione (Example D, 0.05 g, 0.2 mmol) and triethylamine (0.06 mL, 0.4 mmol) in 20 mL of acetonitrile. The solution was heated to reflux for 23 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, water, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.03 g of the title compound as a solid, mp 173-175°C.

Example 5

1-(1-Ethyl-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl-methyl]-carbamic acid, tert-butyl ester

N-Boc-3-aminomethylpyrrolidine (0.2 g, 1.0 mmol) was added to a solution of 1-ethyl-6,7-difluoro-3-hydroxy-1H-quinazoline-2,4-dione (Example D, 0.2 g, 0.8 mmol) and triethylamine (0.23 mL, 1.7 mmol) in 20 mL of acetonitrile. The solution was heated to reflux for 23 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, water, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.34 g of the title compound as a solid, mp 121-124°C.

-88-

Example 6

7-(3-Aminomethyl-pyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, hydrochloride

5 Hydrogen chloride gas was bubbled into a solution of 1-(1-ethyl-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-ylmethyl]-carbamic acid, tert-butyl ester (Example 5, 0.24 g, 0.57 mmol) in 20 mL of methylene chloride at 0°C for 10 minutes. The solution became a suspension, and it was stirred for 24 hours. The mixture was filtered and dried to give 0.17 g of the title compound as a solid, mp 228-231°C.

10

Example 7

1-Ethyl-6-fluoro-3-hydroxy-7-piperazin-1-yl-1H-quinazoline-2,4-dione

Piperazine (0.06 g, 0.74 mmol) was added to a solution of 1-ethyl-6,7-difluoro-3-hydroxy-1H-quinazoline-2,4-dione (Example D, 0.15 g, 0.6 mmol) and triethylamine (0.17 mL, 1.2 mmol) in 20 mL of acetonitrile. The solution was
15 heated to reflux for 23 hours, cooled, and filtered to give 0.17 g of the title compound as a solid, mp 206-208°C.

Example 8

1-(1-Ethyl-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-methyl-3-yl-methyl]-carbamic acid, tert-butyl ester

20 N-Boc-3-methyl-3-aminomethylpyrrolidine (0.16 g, 0.74 mmol) was added to a solution of 1-ethyl-6,7-difluoro-3-hydroxy-1H-quinazoline-2,4-dione (Example D, 0.15 g, 0.6 mmol) and triethylamine (0.17 mL, 1.2 mmol) in 20 mL of acetonitrile. The solution was heated to reflux for 23 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform, washed with 1N
25 HCl, water, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.15 g of the title compound as a solid.
NMR (CDCl₃): δ 8.28 (bs, 1H), 7.64 (d, 1H), 6.06 (d, 1H), 4.67 (m, 1H), 4.11 (q, 2H), 3.63 (m, 2H), 3.40 (m, 1H), 3.20 (m, 2H), 3.07 (m, 1H), 1.87 (m, 1H), 1.67 (m, 1H), 1.49 (s, 3H), 1.38 (s, 9H), 1.30 (t, 3H).

-89-

Example 9

7-(3-Aminomethyl-3-methyl-pyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, hydrochloride

Hydrogen chloride gas was bubbled into a solution of 1-(1-ethyl-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-methyl-3-ylmethyl]-carbamic acid tert-butyl ester (Example 8, 0.13 g, 0.29 mmol) in 20 mL of methylene chloride at 0°C for 10 minutes. The solution became a suspension, and it was stirred for 24 hours. The mixture was concentrated to give 0.08 g of the title compound as a foam, mp 209-211°C.

Example 10

6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Twenty percent Pd/C (50 mg) was added to a solution of 3-benzyloxy-6-fluoro-7-pyrrolidinyl-1H-quinazoline-2,4-dione (Example I, 0.21 g, 0.6 mmol) in 100 mL of THF and 100 mL of methanol. The mixture was shaken under 50 PSI of hydrogen for 4.5 hours, filtered, and concentrated to afford 0.18 g of the title compound as a solid, mp >250°C.

Example 11

1-(6-Fluoro-3-hydroxy-1H-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid, tert-butyl ester

Twenty percent Pd/C (50 mg) was added to a solution of 1-(3-benzyloxy-6-fluoro-1H-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid, tert-butyl ester (Example J, 0.22 g, 0.47 mmol) in 25 mL of THF and 25 mL of methanol. The mixture was shaken under 50 PSI of hydrogen for 1.5 hours, filtered, and concentrated to afford 0.15 g of the title compound as a solid.

Example 12

6-Fluoro-3-hydroxy-1-methyl-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Pyrrolidine (0.07 mL, 0.8 mmol) was added to a solution of 6,7-difluoro-3-hydroxy-1-methyl-1H-quinazoline-2,4-dione (Example L, 0.15 g, 0.66 mmol) and triethylamine (1.2 mL, 8.6 mmol) in 30 mL of acetonitrile. The solution was

-90-

warmed to reflux for 18 hours, cooled, and filtered to give a solid. The solid was triturated with chloroform, filtered, and dried to give 0.07 g of the title compound as a solid, mp >250°C.

Example 13

5 7-(3-Amino-pyrrolidin-1-yl)-6-fluoro-3-hydroxy-1-methyl-1H-quinazoline-2,4-dione, Hydrochloride

N-Boc-3-aminopyrrolidine (0.35 g, 1.9 mmol) was added to a solution of 6,7-difluoro-3-hydroxy-1-methyl-1H-quinazoline-2,4-dione (Example L, 0.2 g, 0.88 mmol) and triethylamine (1.7 mL, 12.1 mmol) in 30 mL of acetonitrile. The solution was warmed to reflux for 90 hours, cooled, and concentrated to a solid. The solid was dissolved in chloroform washed with 1N HCl, water, brine, and dried over magnesium sulfate. The solution was concentrated to give 0.39 g of a solid. The solid was purified by column chromatography (chloroform/methanol 9:1). The appropriate fractions were combined to give 0.14 g of a solid, mp 164-166°C. The solid was redissolved in 20 mL of methylene chloride, and HCl gas was bubbled in at 0°C for 10 minutes. The solution became a suspension, and it was stirred for 24 hours. The resulting precipitate was filtered and dried to give 0.1 g of the title compound as a solid, mp 220-222°C.

20 **General Method 6. Two procedures for the deprotection of 1-(substituted phenyl)-3-benzyloxy-7-aminonucleophile-1H-quinazoline-2,4-diones**

Method A. Ten percent Pd/C (33% w/w) was added to a solution of 1-(substituted phenyl)-3-benzyloxy-7-aminonucleophile-1H-quinazoline-2,4-dione in 25 mL of THF and 25 mL of methanol. The mixture was stirred under atmospheric pressure of hydrogen for 1.5 hours, and filtered. The catalyst was rinsed with 200 mL of methanol and the combined organic fractions were concentrated to afford the product as a solid.

Method B. A 1 M TFA solution of B(TFA)₃ (3 equivalents) was added to a solution of 1-(substituted phenyl)-3-benzyloxy-7-aminonucleophile-1H-quinazoline-2,4-dione (1 equivalent) in 10 mL of TFA at 0°C with stirring. The mixture was stirred under nitrogen at 0°C for 10 minutes, then the cooling bath

-91-

was removed, and the reaction mixture was allowed to warm to room temperature. Solvents were evaporated and the residue dissolved in methanol. The resulting solution was heated at reflux for 10 minutes, cooled to room temperature, and evaporated to dryness in vacuo. This procedure with methanol was repeated
5 two times to afford the product as a solid.

Example 14

1-(4-Hydroxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Using the General Method 6B, the reaction of 1 M TFA solution of
10 B(TFA)₃ (0.5 mL, 0.44 mmol) with 1-(4-hydroxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example K-1, 0.05 g, 0.11 mmol) afforded 0.038 g of the title compound as a solid, mp 264-268°C (decomp.).

Example 15

15 1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Using the General Method 6A, the reaction of 10% Pd/C (0.027 g) with 1-(4-fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example L-1, 0.08 g, 0.18 mmol) afforded 0.05 g of the title compound as a solid, mp 183-185°C.

20 Example 16

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate

Using the General Method 6B, the reaction of 1 M TFA solution of B(TFA)₃ (0.63 mL, 0.63 mmol) with 1-(4-fluorophenyl)-6-fluoro-3-benzyloxy-
25 7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione (Example M-1, 0.1 g, 0.21 mmol) afforded 0.08 g of the title compound as a solid, mp 153-154°C (decomp.).

-92-

Example 17

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride

5 Using the General Method 6A, the reaction of 10% Pd/C (0.075 g) with 1-(4-fluorophenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione (Example N-1, 0.225 g, 0.4 mmol) afforded 0.182 g of 1-(4-fluorophenyl)-6-fluoro-3-hydroxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione.

10 This material was dissolved in 20 mL of dichloromethane and a stream of HCl gas was bubbled through for 10 minutes at 0°C. The mixture was allowed to stir for an additional 24 hours when it was concentrated to give 0.131 g of the title compound as a solid, mp 197-198°C (decomp.)

Example 18

15 1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Using the General Method 6A, the reaction of 10% Pd/C (0.03 g) with 1-(4-methoxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example O-1, 0.09 g, 0.195 mmol) afforded 0.086 g of the title compound as a solid, mp 224-226°C.

20 Example 19

1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

25 Using the General Method 6A, the reaction of 10% Pd/C (0.057 g) with 1-(4-methoxyphenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione (Example P-1, 0.17 g, 0.35 mmol) afforded 0.13 g of the title compound as a solid, mp 195-196°C.

-93-

Example 20

1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride

5 Using the General Method 6A, the reaction of 10% Pd/C (0.074 g) with 1-(4-methoxy phenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione (Example Q-1, 0.222 g, 0.38 mmol) afforded 0.185 g of 1-(4-methoxyphenyl)-6-fluoro-3-hydroxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione as a solid.

10 This material was dissolved in 20 mL of dichloromethane, and a stream of HCl gas was bubbled through for 10 minutes at 0°C. The mixture was allowed to stir for an additional 24 hours, when it was concentrated to give 0.136 g of the title compound as a solid, mp 209-210°C (decomp.).

Example 21

15 1-(3-Chloro-4-fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

Using the General Method 6A, the reaction of 10% Pd/C (0.06 g) with 1-(3-chloro-4-fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione (Example R-1, 0.12 g, 0.23 mmol) afforded 0.085 g of the title compound as a solid, mp 197-199°C.

20 Example 22

1-(3-Chloro-4-fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate

25 Using the General Method 6B, the reaction of 1 M TFA solution of B(TFA)₃ (1.0 mL, 1.0 mmol) with 1-(3-chloro-4-fluoro-phenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione (Example S-1, 0.19 g, 0.37 mmol) afforded 0.06 g of the title compound as a solid, mp 229-231°C.

-94-

Example 23

1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

5 Using the General Method 6A, the reaction of 10% Pd/C (0.04 g) with 1-(3-methoxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example T-1, 0.12 g, 0.26 mmol) afforded 0.09 g of the title compound as a solid, mp 216-218°C.

Example 24

10 1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

Using the General Method 6A, the reaction of 10% Pd/C (0.04 g) with 1-(3-methoxyphenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione (Example U-1, 0.12 g, 0.24 mmol) afforded 0.08 g of the title compound as a solid, mp 158-160°C.

15 Example 25

1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride

20 Using the General Method 6A, the reaction of 10% Pd/C (0.05 g) with 1-(3-methoxyphenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione (Example V-1, 0.15 g, 0.26 mmol) afforded 0.12 g of 1-(3-methoxyphenyl)-6-fluoro-3-hydroxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione as a solid.

25 This material was dissolved in 20 mL of dichloromethane, and a stream of HCl gas was bubbled through for 10 minutes at 0°C. The mixture was allowed to stir for an additional 24 hours, when it was concentrated to give 0.10 g of the title compound as a solid, mp 215-217°C (decomp.).

-95-

Example 26

1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

5 Using the General Method 6A, the reaction of 10% Pd/C (0.03 g) with 1-(2-fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example W-1, 0.1 g, 0.22 mmol) provided 0.07 g of the title compound as a solid, mp 235-237°C.

Example 27

10 1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

Using the General Method 6A, the reaction of 10% Pd/C (0.03 g) with 1-(2-fluorophenylamino)-6-fluoro-3-benzyloxy-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione (Example X-1, 0.09 g, 0.18 mmol) provided 0.07 g of the title compound as a solid, mp 160-162°C.

15 Example 28

1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

20 Using the General Method 6A, the reaction of 10% Pd/C (0.03 g) with 1-(3-fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example Y-1, 0.1 g, 0.22 mmol) provided 0.09 g of the title compound as a solid, mp 239-241°C.

Example 29

1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione

25 Using the General Method 6A, the reaction of 10% Pd/C (0.07 g) with 1-(3-fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione (Example Z-1, 0.209 g, 0.43 mmol) provided 0.11 g of the title compound as a solid, mp 176-178°C.

-96-

Example 30

1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate

5 Using the General Method 6B, the reaction of 1 M TFA solution of B(TFA)₃ (1.3 mL, 1.3 mmol) with 1-(3-fluorophenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonyl-amino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione (Example A-2, 0.231 g, 0.41 mmol) afforded 0.11 g of the title compound as a solid, mp 214-216°C.

Example 31

10 1-(2,4,5-Trifluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate

Using the General Method 6B, the reaction of 1 M TFA solution of B(TFA)₃ (0.6 mL, 0.6 mmol) with 1-(2,4,5-trifluoro-phenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxy-carbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione (Example B-2, 0.13 g, 0.2 mmol) afforded 0.063 g of the title compound as a solid, mp 240-242°C (decomp.).

Example 32

1-Cyclopropyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

20 A suspension of 3-benzyloxy-1-cyclopropyl-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example K-2, 60 mg, 0.152 mmol) and 10% Pd/C (30 mg) in MeOH (3 mL) was stirred at room temperature in hydrogen atmosphere provided by a balloon for 30 minutes. Filtration and concentration of the filtrate gave a solid residue, which was further washed with 10% of
25 dichloromethane/hexane to give 40 mg of the title compound as powder, mp 238°C (decomp.).

-97-

Example 33

1-Cyclopropyl-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione, hydrochloride

Following the procedure of Example 32, the reaction of 3-benzyloxy-1-cyclopropyl-6-fluoro-7-(4-methylpiperazin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example L-2, 65 mg, 0.157 mmol), 10% Pd/C (30 mg) in MeOH (3 mL) under a hydrogen atmosphere, followed by adding a few drop of acetyl chloride into the reaction mixture provided 45 mg of the title compound as powder, mp >300°C (decomp.).

10 Example 34

1-Ethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Following the procedure of Example 32, hydrogenation of 3-benzyloxy-1-ethyl-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example X-2, 110 mg, 0.286 mmol) and 10% Pd/C (60 mg) in MeOH (2 mL) and ethyl acetate (3 mL) afforded 55 mg, of the title compound as a solid, mp 236-237°C (decomp.).

Example 35

1-Ethyl-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-
pyrido[2,3-d]pyrimidine-2,4-dione

Following the procedure of Example 32, hydrogenation of 3-benzyloxy-1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example Y-2, 187 mg, 0.450 mmol) and 10% Pd/C (35 mg) in MeOH (5 mL) afforded 105 mg of the title compound as a solid, mp 219-220°C (decomp.).

Example 36

7-(3-Aminopyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-
pyrido[2,3-d]pyrimidine-2,4-dione, trifluoroacetate

To a solution of 3-benzyloxy-1-ethyl-6-fluoro-7-[3-(N-*tert*-
butoxycarbonylamino)-pyrrolidin-1-yl]-1H-pyrido[2,3-d]pyrimidine-2,4-dione

-98-

(Example Z-2, 230 mg, 0.46 mmol) in trifluoroacetic acid (TFA) (3 mL) was added 1 M B(TFA)₃ in TFA (1.4 mL, 1.4 mmol) at 0°C, and stirring was continued at room temperature for 30 minutes. The mixture was evaporated under reduced pressure, and the residue was dissolved in MeOH (3 mL), refluxed for 1 hour and concentrated into 1 mL. White powder precipitated, when the methanolic solution was diluted with dichloromethane (5 mL) and cooled in an ice-water bath. Filtration and drying in vacuo provided the title compound (150 mg, 77%) as solid, mp 258°C.

Example 37

10 1-Benzyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Following the procedure of Example 32, hydrogenation of 1-benzyl-3-benzyloxy-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example A-3, 110 mg, 0.247 mmol) and 10% Pd/C (15 mg) in MeOH (2 mL) and ethyl acetate (3 mL) afforded 67 mg, of the title compound as a solid, mp 219-220°C.

Example 38

1-Cyclopropyl-6-fluoro-3-hydroxy-7-(pyrrolidin-1-yl)-1H-quinazoline-2,4-dione

20 A solution of 3-benzyloxy-1-cyclopropyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example F-3, 0.15 g, 0.38 mmol) in trifluoroacetic acid (TFA, 3.0 mL) was reacted with a 1.0 M solution of boron tris(trifluoroacetate) (1.5 mL, 1.5 mmol, *Angew. Chem. Internat. Ed.*, 1973;12:147) in TFA and allowed to stir for 2 hours. The mixture was then concentrated and the residue diluted in methanol and concentrated. This process was repeated two times. The residue was then triturated from diethyl ether/hexanes and filtered to provide 0.073 g of the title compound as solid, mp 248-250°C (dec.).

-99-

Example 39

7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione

5 A solution of [1-(3-benzyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester (Example G-3, 0.10 g, 0.22 mmol) in trifluoroacetic acid (TFA, 3.0 mL) was reacted with a 1.0 M solution of boron tris(trifluoroacetate) (1.1 mL, 1.1 mmol) in TFA and allowed to stir for 3 hours. The mixture was then concentrated and the residue rediluted in methanol and concentrated. This process was repeated two
10 times. The residue was then triturated from diethyl ether and filtered to provide 0.075 g of the title compound as a solid, mp 244-245°C (dec.).

Example 40

7-(3-Aminomethyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate

15 A solution of [1-(3-benzyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-ylmethyl]-carbamic acid tert-butyl ester (Example H-3, 0.127 g, 0.24 mmol) in trifluoroacetic acid (TFA, 3.0 mL) was reacted with a 1.0 M solution of boron tris(trifluoroacetate) (1.5 mL, 1.5 mmol) in TFA and allowed to stir for 3 hours. The mixture was then concentrated and the
20 residue rediluted in methanol and concentrated again. This process was repeated three times. The residue was then triturated from diethyl ether and filtered to provide 0.095 g of the title compound as a solid, mp 146-148°C.

Example 41

25 7-(3-Amino-azetidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate

A solution of [1-(3-benzyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-azetidin-3-yl]-carbamic acid tert-butyl ester (Example I-3, 0.13 g, 0.26 mmol) in trifluoroacetic acid (TFA, 3.0 mL) was reacted with a 1.0 M solution of boron tris(trifluoroacetate) (2.0 mL, 1.0 mmol) in
30 TFA and allowed to stir for 2 hours. The mixture was then concentrated and the residue diluted in methanol and concentrated again. This process was repeated

-100-

three times. The residue was then triturated from diethyl ether and filtered to provide 0.097 g of the title compound as a solid, mp 214-216°C (dec.).

Example 42

5 (1 α ,5 α ,6 α)7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate

A solution of (1 α ,5 α ,6 α)[3-(3-benzyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester (Example J-3, 0.19 g, 0.36 mmol) in trifluoroacetic acid (TFA, 4.0 mL) was reacted with a 1.0 M solution of boron
10 tris(trifluoroacetate) (1.8 mL, 1.8 mmol) in TFA and allowed to stir for 2 hours. The mixture was concentrated and the residue dissolved in methanol and concentrated again. This process was repeated three times. The residue was triturated from diethyl ether and filtered to provide 0.134 g of the title compound as a solid, mp 200-201°C (dec.).

15 Example 43

(4 α S-cis)1-Cyclopropyl-6-fluoro-3-hydroxy-7-(octahydro-pyrrolo[3,4-b]pyridin-6-yl)-1H-quinazoline-2,4-dione, trifluoroacetate

A solution of (4 α R-(4 α ,7 α)6-(3-benzyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-octahydro-pyrrolo[3,4-b]pyridine-1-carboxylic acid tert-butyl ester (Example K-3, 0.215 g, 0.39 mmol) in
20 trifluoroacetic acid (TFA, 4.0 mL) was reacted with a 1.0 M solution of boron tris(trifluoroacetate) (2.0 mL, 2.0 mmol) in TFA and allowed to stir for 2 hours. The mixture was concentrated and the residue dissolved in methanol and concentrated again. This process was repeated three times. The residue was
25 triturated from diethyl ether and filtered to provide 0.16 g of the title compound as a solid, mp 190-192°C (dec.).

-101-

Example 44

8-Fluoro-5-hydroxy-9-pyrrolidin-1-yl-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione

5 A solution of 5-benzyloxy-8-fluoro-9-pyrrolidin-1-yl-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione (Example P-3, 0.120 g, 0.29 mmol) in trifluoroacetic acid (3.0 mL) was reacted with a 1.0 M solution of boron tris(trifluoroacetate) (1.74 mL, 1.74 mmol) in TFA and allowed to stir for 3 hours. The mixture was concentrated and the residue dissolved in methanol and concentrated again. This process was repeated three times. The residue was
10 triturated from diethyl ether and filtered to provide the 0.084 g of the title compound as a solid, mp 182-184°C.

Example 45

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione, trifluoroacetate

15 A solution of [1-(5-benzyloxy-8-fluoro-4,6-dioxo-2,3,5,6-tetrahydro-4H-1-thia-3 α ,5-diaza-phenalen-9-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester (Example Q-3, 0.187 g, 0.353 mmol) in trifluoroacetic acid (3.0 mL) was reacted with a 1.0 M solution of boron tris(trifluoroacetate) (2.12 mL, 2.12 mmol) in TFA and allowed to stir for 2 hours. The mixture was concentrated and the residue
20 dissolved in methanol and concentrated again. This process was repeated three times. The residue was triturated from diethyl ether and filtered to provide 0.154 g of the title compound as a solid, mp 232-234°C.

Example 46

(1 α ,5 α ,6 α)9-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-8-fluoro-5-hydroxy-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione, trifluoroacetate

25 A solution of (1 α ,5 α ,6 α)[3-(5-benzyloxy-8-fluoro-4,6-dioxo-2,3,5,6-tetrahydro-4H-1-thia-3 α ,5-diaza-phenalen-9-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester (Example R-3, 0.200 g, 0.38 mmol) in trifluoroacetic acid (3.0 mL) was reacted with a 1.0 M solution of boron
30 tris(trifluoroacetate) (1.92 mL, 1.92 mmol) in TFA and allowed to stir for 2 hours.

-102-

The mixture was concentrated and the residue dissolved in methanol and concentrated again. This process was repeated three times. The residue was triturated from diethyl ether and filtered to provide 0.17 g of the title compound as a solid, mp 185-187°C.

5

Example 47

1-Cyclopropyl-6,8-difluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

A solution of 3-tert-butoxy-1-cyclopropyl-6,8-difluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example U-3, 0.52 g) in TFA (10 mL) was allowed to stir overnight at ambient temperature. The mixture was then concentrated and the product triturated with diethyl ether (repeated three times). The solid was filtered and washed with diethyl ether and dried to provide 0.35 g of the title compound as a solid, mp 228-230°C.

10

Example 48

15 1-Ethyl-5,6,8-trifluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

A solution of 3-benzyloxy-1-ethyl-5,6,8-trifluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example X-3, 0.15 g, 0.36 mmol) in trifluoroacetic acid (5.0 mL) was reacted with a 1.0 M solution of boron tris(trifluoroacetate) (1.8 mL, 1.8 mmol) in TFA and allowed to stir for 1 hour. The mixture was then concentrated and the residue dissolved in methanol and concentrated. This process was repeated three times. The residue was then triturated from diethyl ether and filtered to provide 0.11 g of the title compound as a solid, mp 223-225°C.

20

Example 49

1-Benzyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Phenylsilane (0.07 mL, 0.56 mmol) and palladium tetrakis(triphenylphosphine) (17 mg, 0.015 mmol) were added to a solution of 3-allyloxy-1-benzyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example B-4, 0.15 g, 0.4 mmol) in 10 mL of dichloromethane at 0°C. The mixture was stirred for 17 hours and filtered to give 0.06 g of the title compound as a solid, mp 234-236°C.

25

30

-103-

Example 50

1-Benzyl-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione

Phenylsilane (0.09 mL, 0.71 mmol) and palladium
5 tetrakis(triphenylphosphine) (21 mg, 0.019 mmol) were added to a solution of
1-(3-allyloxy-1-benzyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-
pyrrolidin-3-yl]-carbamic acid tert-butyl ester (Example C-4, 0.24 g, 0.4 mmol) in
3 mL of dichloromethane at 0°C. The mixture was stirred for 17 hours and filtered
to give 0.08 g of a solid. The filtrate was purified by column chromatography
10 (silica gel, CHCl₃/MeOH, 80:20) to give an additional 0.06 g. The solids were
combined to give 0.14 g 1-benzyl-6-fluoro-3-hydroxy-2, 4-dioxo-1,2,3,4-
tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester as a
solid. This material was dissolved in 20 mL of dichloromethane at 0°C and a
stream of HCl was bubbled in for 10 minutes. The solution became a suspension
15 and it was stirred for 24 hours. The mixture was filtered and dried to give 0.08 g
of the title compound as a solid.

Example 51

1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Twenty percent Pd/C (25 mg) was added to a solution of 3-benzyloxy-
20 1-(2-fluoroethyl)-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione
(Example E-4, 0.17 g, 0.4 mmol) in 50 mL of THF, this was shaken under 50 PSI
of hydrogen for 14.5 hours. The mixture was filtered and concentrated to afford
0.16 g of a solid, which was triturated with ether and dried to give 0.07 g of the
title compound as a solid, mp 228-230°C.

25 Example 52

1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester

Twenty percent Pd/C (25 mg) was added to a solution of 1-(3-benzyloxy-
1-(2-fluoroethyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-
30 pyrrolidin-3-yl]-carbamic acid tert-butyl ester (Example F-4, 0.20 g, 0.38 mmol)

-104-

in 50 mL of THF. This was shaken under 50 PSI of hydrogen for 6.3 hours. The mixture was filtered and concentrated to afford 0.16 g of the title compound.

Example 53

5 1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-7-(ethyl-pyrrolidin-3-ylmethyl-amine-1-yl)-1H-quinazoline-2,4-dione

Twenty percent Pd/C (25 mg) was added to a solution of 3-benzyloxy-1-(2-fluorethyl)-6-fluoro-7-(ethyl-pyrrolidin-3-ylmethyl-amine -1-yl)-1H-quinazoline-2,4-dione (Example G-4, 0.15 g, 0.33 mmol) in 16 mL of THF; this was shaken under 50 PSI of hydrogen for 14.5 hours. The mixture was filtered and concentrated, and the solid formed was triturated with ether and dried to give 10 0.07 g of the title compound as a solid.

Example 54

15 1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Twenty percent Pd/C (50 mg) was added to a solution of 3-benzyloxy-1-(2,4-difluorophenyl)-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example K-4, 0.22 g, 0.5 mmol) in 40 mL of THF, and this was shaken under 50 PSI of hydrogen for 16 hours. The mixture was filtered and concentrated to afford 0.19 g of a solid. This solid was triturated with ether and filtered to give 20 0.08 g of the title compound as a solid, mp 232-234°C.

Example 55

25 1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride

Twenty percent Pd/C (50 mg) was added to a solution of 1-(3-benzyloxy-1-(2,4-difluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester (Example L-4, 0.23 g, 0.4 mmol) in 16 mL of THF, and this was shaken under 50 PSI of hydrogen for 2.5 hours. The mixture was filtered and concentrated to give 0.22 g of 1-(2,4-difluorophenyl)-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester. This material was dissolved in 10 mL of 30

-105-

dichloromethane and reacted with a stream of HCl gas at 0°C for 10 minutes. The solution became a suspension and it was stirred for 17 hours. The mixture was filtered and dried to give 0.12 g of the title compound as a solid, mp >250°C.

Example 56

5 6-Fluoro-1-(4-fluorophenyl)-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Twenty percent Pd/C (70 mg) was added to a solution of 3-benzyloxy-6-fluoro-1-(4-fluorophenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example N-4, 0.15 g, 0.33 mmol) in 25 mL of THF, and this was
10 shaken under 50 PSI of hydrogen for 17.5 hours. The mixture was filtered and concentrated to give 0.13 g of the title compound as a solid, mp 172-174°C.

Example 57

1-Butyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

15 Twenty percent Pd/C (70 mg) was added to a solution of 3-benzyloxy-1-butyl-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example O-4, 0.13 g, 0.32 mmol) in 25 mL of THF, and this was shaken under 50 PSI of hydrogen for 17.5 hours. The mixture was filtered and concentrated to give 0.11 g of the title compound as a solid, mp 153-155°C.

20

Example 58

6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1-(4-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the method of Example 56, 20% Pd/C (30 mg), 3-benzyloxy-6-fluoro-7-pyrrolidin-1-yl-1-(4-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example P-4, 0.17 g, 0.34 mmol) were
25 combined in 50 mL of THF, to give 0.14 g of the title compound as a solid, mp 203-205°C.

-106-

Example 59

1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

5 Using the method of Example 56, 20% Pd/C (40 mg), 3-benzyloxy-1-(2,4-difluorophenyl)-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example Q-4, 0.15 g, 0.33 mmol) were combined in 50 mL of THF, to give 0.06 g of the title compound as a solid, mp 189-191°C.

Example 60

10 6-Fluoro-3-hydroxy-1-(4-methylphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the method of Example 56, 20% Pd/C (20 mg), 3-benzyloxy-6-fluoro-1-(4-methylphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example R-4, 0.16 g, 0.33 mmol) were combined in 25 mL of THF, to give 0.11 g of the title compound as a solid, mp 228-230°C.

15 Example 61

6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1-(3-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione

20 Using the method of Example 56, 20% Pd/C (25 mg), 3-benzyloxy-6-fluoro-7-pyrrolidin-1-yl-1-(3-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example S-4, 0.17 g, 0.34 mmol) were combined in 25 mL of THF, to give 0.08 g of the title compound as a solid, mp 136-138°C.

Example 62

25 1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

Using the method of Example 56, 20% Pd/C (25 mg), 3-benzyloxy-1-(2-fluorophenyl)-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example T-4, 0.14 g, 0.31 mmol) were combined in 25 mL of THF, to give 0.13 g of the title compound as a solid, mp >250°C.

-107-

Example 63

6-Fluoro-3-hydroxy-1-(4-methoxyphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione

5 Using the method of Example 56, 20% Pd/C (20 mg), 3-benzyloxy-6-fluoro-1-(4-methoxyphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione (Example U-4, 0.16 g, 0.34 mmol) were combined in 15 mL of THF, to give 0.11 g of the title compound as a solid.

Example 64

10 1-Cyclopropylmethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione

Using the method of Example 56, 20% Pd/C (25 mg), 3-benzyloxy-1-cyclopropylmethyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione (Example V-4, 0.16 g, 0.39 mmol) were combined in 25 mL of THF, to give 0.06 g of the title compound as a solid, mp 211-213°C.

15 Example 65

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione, hydrochloride

20 Using the method of Example 55, 20% Pd/C (30 mg), and 1-(3-benzyloxy-1-(4-fluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester (Example X-4, 0.26 g, 0.42 mmol) were combined in 12 mL of THF, to give 0.19 g of 1-[(4-fluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-7-yl]-carbamic acid tert-butyl ester. This was dissolved in 20 mL of dichloromethane and treated with HCl gas to afford 0.14 g of the title compound
25 as a solid, mp 235-238°C.

-108-

Example 66

(1 α .5 α .6 α)[3-(1-(4-fluorophenyl)-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro pyrido[2,3-d]pyrimidine-7-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester

5 Using the method of Example 56, 20% Pd/C (30 mg), (1 α .5 α .6 α)[3-(3-Benzyloxy-1-(4-fluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro pyrido[2,3-d]pyrimidine-7-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester (Example Y-4, 0.19 g, 0.33 mmol) were combined in 25 mL of THF, to give 0.19 g of the title compound as a foam.

10 The compounds of the current invention were evaluated to demonstrate their desired antibacterial activities and inhibition of bacterial enzymes, and versus the undesired cell cytotoxicity.

Antibacterial assay: The compounds of the present invention were tested against an assortment of Gram negative and Gram positive organisms using
15 standard microtitration techniques (Cohen, et al., *Antimicrob. Agents Chemother.*, 1985;28:766; Heifetz, et al., *Antimicrob. Agents Chemother.*, 1974;6:124). The results of the evaluation are shown in Table 1.

-109-

TABLE 1. Antibacterial Activity

Example Number	Minimum Inhibitory Concentrations µg/mL					
	Gram Negatives			Gram Positives		
	<i>E. coli</i> MC4100	<i>E. coli</i> B90	<i>E. coli</i> Tol C	<i>B. subtilis</i> RB1	<i>S. aureus</i> 29213	<i>S. pyogenes</i> C203
1	>64	2.0	1.0	4.0	32	32
2	16	4.0	2.0	16	>64	>64
3	>64	4.0	2.0	8.0	>64	>64
4	>64	16	16	8.0	64	64
6	64	8.0	8.0	32	64	16
7	16	4.0	8.0	>64	>64	>64
9	16	4.0	2.0	16	16	8.0
14	64	4.0	1.0	--	32	64
17	>64	64	32	--	>64	32
23	>64	32	32	--	32	32
28	>64	2.0	2.0	--	32	32
32	>64	0.5	0.5	--	8.0	64
36	8.0	2.0	2.0	--	64	32
38	8.0	0.1	0.1	0.25	1.0	16
39	1.0	0.3	0.25	2.0	32	4.0
42	1.0	0.25	0.25	--	4.0	2.0
44	>64	1.0	1.0	--	4.0	32
46	8.0	2.0	1.0	--	>64	32
56	16	0.13	0.13	--	8.0	8.0

DNA gyrase assay: The effects of test agents on the activity of DNA gyrase was determined by the supercoiling inhibition assay, following reaction conditions recommended by the enzyme supplier (Lucent, Ltd., Leicester, UK), as follows. Reactions were performed in buffer G (35 mM Tris-HCl (pH 7.5), 24 mM KCl, 4 mM MgCl₂, 2 mM DTT, 1.8 mM spermidine, 1 mM ATP, 0.1 mg/mL bovine serum albumin). 0.25 µg of relaxed plasmid pBR322 (Lucent, Ltd., Leicester, UK) was reacted with 1 U *E. coli* gyrase (Lucent, Ltd., Leicester, UK), in the absence or presence of drugs, for 30 minutes at 37°C. Reactions were stopped by the addition of SDS and proteinase K to respective final concentrations of 1% and 0.5 mg/mL. After an additional 30 minutes at 37°C, one-tenth volume

-110-

of 10X loading buffer (0.3% bromophenol blue, 16% Ficoll, 10 mM Na₂HPO₄) was added, and reactions were loaded onto agarose gels and electrophoresed as described above for intercalation assays. The concentration of drug inhibiting 50% of the supercoiling activity of DNA gyrase is given as an IC₅₀ and recorded in Table 2.

TABLE 2. Inhibitory Activities vs DNA Gyrase and Topoisomerase IV

Example Number	Gyrase IC ₅₀ (μM)	DNA TopIV IC ₅₀ (μM)
2	22	>100
6	5.5	59
7	>100	49
9	15.5	>100
14	46	--
23	36	>100
32	6.4	>100
38	6.6	57
39	2.4	9
42	0.76	28
44	12	>100
46	8.3	--

Topoisomerase IV assay: Topoisomerase IV was purified from *E. coli* overexpressing strains, and the compounds were assayed according to literature conditions (*Journal of Biological Chemistry*, 1993;268(32):24481). The k-DNA decatenation assay was used. Briefly, reactions were performed in buffer R (40 mM Tris-HCl (pH 7.5), 6 mM MgCl₂, 10 mM DTT, 100 mM potassium glutamate, 40 μM ATP, 50 μg/mL bovine serum albumin, 10 mM NaCl). Two-tenths microgram of kinetoplast DNA (k-DNA; TopoGen, Columbus, OH) was incubated with 5 ng of *E. coli* Topoisomerase IV in the presence or absence of test compounds for 10 minutes at 37°C. Subsequently, one-tenth volume of 10X

-111-

gel loading buffer (0.3% bromophenol blue, 16% Ficoll, 10 mM Na₂HPO₄) was added, and samples were loaded onto horizontal 0.8% agarose gels prepared with TBE buffer and containing 0.05 µg/mL of ethidium bromide. Electrophoresis was at 70 V for 2 to 4 hours. Gels were then examined by exposure to UV light. The concentration of drug inhibiting 50% of the decatenating activity of Topoisomerase IV is given as an IC₅₀ and recorded in Table 2.

Mammalian Cell Cytotoxicity: Compounds were also evaluated in the mammalian cell cytotoxicity assay following the procedures of Suto, et al., (*J. Med Chem.*, 1992;35:4745) and Ciaravino, et al., (*Mutation Res.*, 1993;298:227). The cytotoxicity was determined in Chinese hamster V79 cells. The cells were grown overnight and treated with drug for 3 hours at 37°C, at which time the compound containing media was replaced with fresh media. The cells were then incubated for 5 days and examined for colony formation. The concentration of the drug inhibiting colony formation by 50% is represented by the IC₅₀ and is recorded in Table 3.

TABLE 3. Cytotoxicity to Mammalian Cells

Example Number	50% Cytotoxic Conc. in CHO Cells (µg/mL)
2	177
3	176


The quinolone mimics described in this invention display Gram-negative and -positive activity. The compounds also show inhibition of bacterial DNA gyrase/DNA Top IV.

Finally, the compounds are not highly cytotoxic to mammalian cells indicating selectivity for bacteria.

-112-

CLAIMS

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof wherein:

5 R_1 is H, a straight or branched alkyl of 1 to 6 carbons, cycloalkyl of 3 to 6 carbons, a heterocycle of 4 to 6 atoms having 1 to 2 heteroatoms, or a phenyl group, each is optionally substituted by R, F, Cl, OR, or $N(R)_2$ wherein R is H, a straight or branched alkyl of 1 to 6 atoms having 0 to 1 degrees of unsaturation, a ring of 3 to 6 atoms having 0 to 2 heteroatoms, 10 or a phenyl group, each may be substituted by F, Cl, CN, NO_2 , OH, NH_2 ; also, two R's may form a 3- to 7-membered ring with the atom to which it is attached which ring may have 0 to 1 heteroatoms;

R_5 , R_6 , and R_8 are each independently H, F, Cl, Br, NO_2 , CN, CF_3 , $(C(R)_2)_nOR$, $(C(R)_2)_nCO_2R$, $(C(R)_2)_nCON(R)_2$, $(C(R)_2)_nN(R)_2$, 15 $(C(R)_2)_nNRCOR$, a straight or branched alkyl of 1 to 4 carbons containing 0 to 1 degrees of unsaturation, a cycloalkyl of 3 to 6 carbons, each optionally substituted by F, Cl, OR, or $N(R)_2$ wherein R is as defined above;

R_1 and R_8 may form a ring of 6 to 7 atoms having 1 to 20 2 heteroatoms which ring may be substituted by one or more R's wherein R is as defined above;

R_7 is selected from R_5 , R_6 , R_8 , a carbocycle of 3 to 7 carbons, a phenyl, or a heterocyclic ring of 4 to 7 atoms, a fused heterocyclic ring of 8 to 10 atoms, a bicyclic heterocycle of 6 to 9 atoms, or a spiro heterocycle

-113-

of 7 to 12 atoms each having 1 to 4 heteroatoms, and each of which is optionally substituted by one or more of R', F, Cl, (C(R)₂)_nN(R)₂, (C(R)₂)_nOR, O, (C(R)₂)_nCON(R)₂, (C(R)₂)_nCOR, (C(R)₂)_nNRCOR, (C(R)₂)_nCO₂R, wherein R is defined above and R' is defined as R which is defined above; any of the adjacent groups R₅-R₈ may together form a 5- to 7-membered ring having 0 to 2 heteroatoms, which rings may be substituted by any of the groups described for R₇;

n is an integer of from 0 to 3; and

X and Y are each independently carbon or nitrogen with the understanding that if X or Y is nitrogen, no substituent R₆ or R₈ is attached.

2. A compound according to Claim 1 wherein:

R₁ is methyl, ethyl, cyclopropyl, *t*-butyl, 2-fluorocyclopropyl, 1- or 2-methylcyclopropyl, cyclopropylmethyl, CH=CH₂, 4-fluorophenyl, or 2,4-difluorophenyl;

R is H, a straight or branched alkyl of 1 to 6 atoms, a ring of 3 to 6 atoms having 0 to 2 heteroatoms, or a phenyl group, each may be substituted by F, Cl, OH, NH₂; alternatively two R's may form a 3- to 7-membered ring having 0 to 2 additional heteroatoms;

R₅, R₆, and R₈ are each independently H, F, Cl, Br, NO₂, CN, CF₃, CH=CH₂, (C(R)₂)_nOR, (C(R)₂)_nCO₂R, (C(R)₂)_nCON(R)₂, (C(R)₂)_nN(R)₂, (C(R)₂)_nNRCOR, a straight or branched alkyl of 1 to 4 carbons, a cycloalkyl of 3 to 6 carbons wherein the alkyl or cycloalkyl is optionally substituted by F, Cl, OR, or N(R)₂;

R₇ is selected from R₅, R₆, R₈, a heterocyclic ring of 4 to 7 atoms, a fused heterocyclic ring of 8 to 10 atoms or a bicyclic heterocycle of 6 to 9 atoms, each having 1 to 4 heteroatoms, and each of which may be substituted by one or more of R', F, Cl, (C(R)₂)_nNR₂, (C(R)₂)_nOR, O, (C(R)₂)_nCONR₂, (C(R)₂)_nCOR, (C(R)₂)_nNRCOR,

-114-

(C(R)₂)_nCO₂R, wherein R' is H, a straight or branched alkyl of 1 to 6 atoms having 0 to 1 degrees of unsaturation, a ring of 3 to 6 atoms having 0 to 2 heteroatoms, or a phenyl group, each may be substituted by F, Cl, CN, NO₂, OH, NH₂; also, two R's may form a 3- to 7-membered ring with the atom to which it is attached which ring may have 0 to 1 heteroatoms;

n is an integer from 0 to 3; and

X and Y are each independently carbon or nitrogen.

3. A compound according to Claim 1 wherein:

any of the adjacent groups R₅-R₈ may together form a 5- to 7-membered ring having 0 to 2 heteroatoms and such rings may be substituted by any of the groups described for R₇;

n is 0 to 3;

R is H, a straight or branched alkyl of 1 to 4 carbons, a ring of 3 to 6 atoms having 0 to 2 heteroatoms or a phenyl, each may be optionally substituted by F, Cl, OH, CN, NO₂, or NH₂; and

X and Y are independently carbon or nitrogen.

4. A compound according to Claim 1 wherein:

R₁ is ethyl, cyclopropyl, 2-fluorocyclopropyl, cyclopropylmethyl, *t*-butyl, or phenyl optionally substituted by F, Cl, OR, or N(R)₂;

R is H, methyl, ethyl, isopropyl, *t*-butyl, or phenyl;

R' is methyl, ethyl, phenyl, or a 2, 3, or 4-pyridyl each of which may be substituted with F, Cl, CH₃, (CH₂)_nN(R)₂, or OR;

R₅, R₆, and R₈ are each independently selected from H, F, Cl, Br, CH₃, NH₂, CH=CH₂, NO₂, and OCH₃;

R₇ is selected from R₅, R₆, R₈, a heterocyclic ring of 4 to 7 atoms, a fused heterocyclic ring of 8 to 10 atoms or a bicyclic heterocycle of 6 to 9 atoms, each having 1 to 4 heteroatoms, and each of which may be substituted by one or more of R', F, Cl, (C(R)₂)_nNR₂, (C(R)₂)_nOR, O,

-115-

$(C(R)_2)_nCON(R)_2$, $(C(R)_2)_nCOR$, $(C(R)_2)_nNRCOR$, $(C(R)_2)_nCO_2R$, a straight or branched alkyl of 1 to 4 atoms, or a phenyl group which may also be substituted as described above;

n is an integer from 0 to 3; and

5 X is a carbon or nitrogen and Y is a carbon.

5. A compound according to Claim 1 wherein:

R₁ is ethyl, cyclopropyl, *t*-butyl, or phenyl, optionally substituted by F, Cl, OR, or NR₂;

10 R₅, R₆, and R₈ are each independently selected from H, F, Cl, Br, CH₃, NH₂, NO₂, and OCH₃;

R₇ is a 5- or 6-membered ring heterocycle, having 1 to 2 heteroatoms, optionally substituted by $(C(R)_2)_nN(R)_2$; a [4.3.0]-bridged heterocycle with 1 to 2 heteroatoms, optionally substituted by $(C(R)_2)_nN(R)_2$; a [3.1.0]-bridged heterocycle having 1 heteroatom, 15 optionally substituted by $(C(R)_2)_nN(R)_2$; a bridged heterocycle of 7 to 9 atoms having 1 to 3 heteroatoms, or a spiro heterocycle of 7 to 12 atoms having 1 to 2 heteroatoms optionally substituted by $(C(R)_2)_nN(R)_2$, which heterocycles may also be substituted by R', F, Cl, or OH;

n is an integer from 0 to 3;

20 R is H, a straight or branched alkyl of 1 to 6 atoms, which may be substituted by F, Cl, OH, NH₂; alternatively two R's may form a 3- to 7-membered ring having 0 to 2 additional heteroatoms;

R' is a straight or branched alkyl of 1 to 4 carbons, a phenyl or a heterocycle of 5 or 6 atoms with 1 or 2 heteroatoms optionally substituted 25 by F, Cl, OH, CN, NO₂, or $(CH_2)_nN(R)_2$; also, two R''s may form a cyclobutyl or a cyclobutyl ring; and

X is carbon or nitrogen; and

Y is carbon.

6. A compound according to Claim 1 wherein:

-116-

R₁ is ethyl, cyclopropyl, cyclopropylmethyl, *t*-butyl, or phenyl, optionally substituted by F, Cl, OR, or N(R)₂;

adjacent groups R₅-R₈ form a 5- or 6-membered ring having 1 to 2 heteroatoms and which may be substituted by any of the groups described above for R₇;

n is 0 to 1;

R is H, a straight or branched alkyl of 1 to 4 carbons, a ring of 3 to 6 atoms having 0 to 2 heteroatoms or a phenyl, optionally substituted by F, Cl, OH, CN, NO₂, or NH₂; and

X and Y are independently carbon or nitrogen with the understanding that if X or Y is nitrogen, no substituent R₆ or R₈ is attached.

7. A compound according to Claim 1 wherein:

R₁ and R₈ form a 6-membered ring having 1 to 2 heteroatoms and where the ring is optionally substituted with H, CH₃, CH₂CH₃, F, or OCH₃;

R is H, a straight or branched alkyl of 1 to 3 atoms or phenyl optionally substituted by F, Cl, OH, or NH₂;

R₅ and R₆ are each independently H, F, Cl, Br, NO₂, NH₂, CH₃, CHCH₂ or R₅ and R₆ may form a ring of 5 to 7 atoms having 0 to 2 heteroatoms;

R₇ is selected from R₅, R₆, cyclopropane, cyclobutane, cyclopentane, cyclohexane, a heterocyclic ring of 4 to 7 atoms, a fused heterocyclic ring of 8 to 10 atoms, or a bicyclic heterocycle of 6 to 9 atoms, each having 1 to 4 heteroatoms, and each of the above may be optionally substituted by one or more of R', F, Cl, (CR₂)_nN(R)₂, (CR₂)_nOR, or O, wherein R' is methyl, ethyl, isopropyl, phenyl, a heterocycle of 5 to 6 atoms having 1 to 2 heteroatoms, each of which may be substituted by F, Cl, CH₃, (CH₂)_nN(R)₂, or OR;

-117-

n is an integer of 0 to 3; and

Y may be carbon or nitrogen.

8. A compound according to Claim 1 wherein:

R₁ is ethyl, cyclopropyl, cyclopropylmethyl, or fluorocyclopropyl;

5 R is H, ethyl, propyl, isopropyl or phenyl, each optionally substituted with F, Cl, OH, or NH₂;

R₅, R₆, and R₈ are each independently H, F, Cl, Br, NO₂, methyl, ethyl, ethylene, or any R₅-R₈ may form a ring of 5 to 6 atoms having 0 to 2 heteroatoms;

10 R₇ is a carbocycle of 3 to 6 atoms, a heterocycle of 5 to 6 atoms having 1 to 2 heteroatoms, a fused heterocycle having 9 atoms and 2 heteroatoms, a bicyclic heterocycle of 6 to 8 atoms having 1 to 2 heteroatoms, each of which may be substituted by one or more of R', F, N(R)₂, CH₂N(R)₂, CH₂CH₂N(R)₂, CH(CH₃)N(R)₂, C(CH₃)₂N(R)₂,
15 CH₂OH, CH₂CH₂OH, or OH, wherein R' is methyl, ethyl, or phenyl optionally substituted by any of the above;

Y is carbon; and

X is carbon or nitrogen.

9. A compound according to Claim 1 wherein:

20 R₁ is ethyl, cyclopropyl, cyclopropylmethyl, *t*-butyl, or phenyl, optionally substituted by F, OH, or NR₂;

R is H, methyl, or ethyl;

R' is methyl, ethyl, phenyl, a heterocycle of 5 to 6 atoms containing 1 to 2 heteroatoms, each of which may be substituted by F, Cl, CH₃,
25 (CH₂)_nN(R)₂, or OR;

R₅ is H, F, or NH₂;


R₆ is H, F, Cl, Br, OCH₃, CH=CH₂, or NO₂;

R₈ is H, F, Cl, Br, CH₃, or OCH₃;


-118-

- R₇ is a 5- or 6-membered ring heterocycle, having 1 to
 2 heteroatoms, optionally substituted by (C(R)₂)_nN(R)₂; a [4.3.0]-bridged
 heterocycle, with 1 to 2 heteroatoms, which may be optionally substituted
 by (C(R)₂)_nN(R)₂; a [3.1.0]-bridged heterocycle, having 1 heteroatom,
 5 which may be optionally substituted by (C(R)₂)_nN(R)₂; a bridged
 heterocycle of 7 to 9 atoms having 1 to 3 heteroatoms, which may be
 optionally substituted by (C(R)₂)_nNR₂, which heterocycles may also be
 substituted by R', F, Cl, or OH;
 n is 0 to 1;
 10 Y is carbon; and
 X is carbon or nitrogen.

10. A compound according to Claim 1 wherein R₇ is selected from:



-119-



wherein the NH or NH₂'s may be substituted with methyl or ethyl.

11. A compound according to Claim 1 selected from:

1-Ethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-Ethyl-6-fluoro-3-hydroxy-7-(4-methyl-piperazin-1-yl)-1H-quinazoline-2,4-dione;

1-Ethyl-6-fluoro-3-hydroxy-7-morpholin-4-yl-1H-quinazoline-2,4-dione;

1-Ethyl-6-fluoro-3-hydroxy-7-piperidin-1-yl-1H-quinazoline-2,4-dione;

1-(1-Ethyl-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-ylmethyl]-carbamic acid, tert-butyl ester;

7-(3-Aminomethyl-pyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, hydrochloride;

1-Ethyl-6-fluoro-3-hydroxy-7-piperazin-1-yl-1H-quinazoline-2,4-dione;

1-(1-Ethyl-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-methyl-3-ylmethyl]-carbamic acid, tert-butyl ester;

-120-

7-(3-Aminomethyl-3-methyl-pyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, hydrochloride;

6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

5 1-(6-Fluoro-3-hydroxy-1H-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid, tert-butyl ester;

6-Fluoro-3-hydroxy-1-methyl-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

6-Fluoro-3-hydroxy-1-methyl-7-(3-amino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride;

10 7-(3-Amino-pyrrolidin-1-yl)-6-fluoro-3-hydroxy-1-methyl-1H-quinazoline-2,4-dione, hydrochloride;

1-(4-Hydroxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

15 1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride;

20 1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

25 1-(4-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride;

1-(3-Chloro-4-fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

1-(3-Chloro-4-fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

30 1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

-121-

1-(3-Methoxyphenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride

1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

5 1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

10 1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

1-(3-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

1-(2,4,5-Trifluorophenyl)-6-fluoro-3-hydroxy-7-(3-aminopyrrolidin-1-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

15 1-Cyclopropyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

1-Cyclopropyl-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione, hydrochloride;

20 1-Ethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

1-Ethyl-6-fluoro-3-hydroxy-7-(4-methylpiperazin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

7-(3-Aminopyrrolidin-1-yl)-1-ethyl-6-fluoro-3-hydroxy-1H-pyrido[2,3-d]pyrimidine-2,4-dione, trifluoroacetate;

25 1-Benzyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

1-Cyclopropyl-6-fluoro-3-hydroxy-7-(pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

30 7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione;

7-(3-Aminomethyl-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate;

-122-

7-(3-Amino-azetidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate;

(1 α ,5 α ,6 α)7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione, trifluoroacetate;

(4 α S-cis)1-Cyclopropyl-6-fluoro-3-hydroxy-7-(octahydro-pyrrolo[3,4-b]pyridin-6-yl)-1H-quinazoline-2,4-dione, trifluoroacetate;

8-Fluoro-5-hydroxy-9-pyrrolidin-1-yl-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione, trifluoroacetate;

(1 α ,5 α ,6 α)9-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-8-fluoro-5-hydroxy-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione, trifluoroacetate;

1-Cyclopropyl-6,8-difluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-Ethyl-5,6,8-trifluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-Benzyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-Benzyl-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester;

1-(2-Fluoroethyl)-6-fluoro-3-hydroxy-7-(ethyl-pyrrolidin-3-ylmethyl-amine-1-yl)-1H-quinazoline-2,4-dione;

1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

-123-

1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione, hydrochloride;

6-Fluoro-1-(4-fluorophenyl)-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

5 1-Butyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1-(4-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

10 1-(2,4-Difluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

6-Fluoro-3-hydroxy-1-(4-methylphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

6-Fluoro-3-hydroxy-7-pyrrolidin-1-yl-1-(3-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

15 1-(2-Fluorophenyl)-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

6-Fluoro-3-hydroxy-1-(4-methoxyphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

20 1-Cyclopropylmethyl-6-fluoro-3-hydroxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-7-(3-amino-pyrrolidin-1-yl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione, hydrochloride;

25 (1 α ,5 α ,6 α)[3-(1-(4-Fluorophenyl)-6-fluoro-3-hydroxy-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-7-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester;

7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6,8-difluoro-3-hydroxy-1H-quinazoline-2,4-dione;

7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-3-hydroxy-1H-quinazoline-2,4-dione;

30 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

-124-

9-(3-Amino-pyrrolidin-1-yl)-3-ethyl-8-fluoro-5-hydroxy-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

5 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

10 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2-methyl-2,3-dihydro-1-oxa-3a,5-diaza-phenalene-4,6-dione;

9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-3-methyl-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione;

15 9-(3-Amino-pyrrolidin-1-yl)-8-fluoro-5-hydroxy-2-methyl-2,3-dihydro-1-thia-3a,5-diaza-phenalene-4,6-dione;

5-Amino-7-(6-amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6,8-difluoro-3-hydroxy-1H-quinazoline-2,4-dione;

20 5-Amino-7-(3-amino-pyrrolidin-1-yl)-1-cyclopropyl-6,8-difluoro-3-hydroxy-1H-quinazoline-2,4-dione;

7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-6,8-difluoro-3-hydroxy-1-(2-methyl-butyl)-1H-quinazoline-2,4-dione;

7-(3-Aminomethyl-3-methyl-pyrrolidin-1-yl)-6-fluoro-3-hydroxy-1-(2-methyl-butyl)-1H-quinazoline-2,4-dione;

25 7-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

7-(3-Amino-pyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-3-hydroxy-1H-quinazoline-2,4-dione;

30 7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-8-methoxy-1H-quinazoline-2,4-dione; and

7-(3-Amino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-3-hydroxy-8-methylsulfanyl-1H-quinazoline-2,4-dione.

-125-

12. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
13. A method for treating bacterial infections in a mammal comprising administering to said mammal a therapeutically effective amount of a compound according to Claim 1.
14. A compound selected from:
- 3-Benzoyloxy-1-ethyl-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 3-Benzoyloxy-6,7-difluoro-1-methyl-1H-quinazoline-2,4-dione;
 - 1-(4-Fluorophenyl)-3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 1-(4-Methoxyphenyl)-3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 1-(3-Chloro-4-fluorophenyl)-3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 1-(3-Methoxyphenyl)-3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 1-(2-Fluorophenyl)-3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 1-(3-Fluorophenyl)-3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 1-(2,4,5-Trifluorophenyl)-3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 1-(4-Hydroxyphenyl)-3-benzoyloxy-6,7-difluoro-1H-quinazoline-2,4-dione;
 - 3-Benzoyloxy-7-chloro-1-ethyl-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione;
 - 3-Benzoyloxy-1-butyl-7-chloro-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione;
 - 1-Benzyl-3-benzoyloxy-7-chloro-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

-126-

3-Benzyloxy-7-chloro-6-fluoro-1-(4-fluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzyloxy-7-chloro-6-fluoro-1-(2-fluorophenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

5 3-Benzyloxy-7-chloro-1-(2,4-difluorophenyl)-6-fluoro-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzyloxy-7-chloro-6-fluoro-1-(4-methylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

10 3-Benzyloxy-7-chloro-6-fluoro-1-(4-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzyloxy-7-chloro-6-fluoro-1-(3-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzyloxy-7-chloro-6-fluoro-1-(4-methoxyphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

15 3-Benzyloxy-7-chloro-1-cyclopropyl-6-fluoro-1H-quinazoline-2,4-dione;

5-Benzyloxy-8,9-difluoro-2,3-dihydro-1-thia-3 α ,5-diazaphenalene-4,6-dione;

20 3-tert-Butoxy-1-cyclopropyl-6,8-difluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

3-Benzyloxy-1-ethyl-5,6,8-trifluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

3-Allyloxy-1-benzyl-6,7-difluoro-1H-quinazoline-2,4-dione;

25 3-Benzyloxy-1-(2-fluoroethyl)-6,7-difluoro-1H-quinazoline-2,4-dione;

3-Benzyloxy-1-(2,4-difluorophenyl)-6,7-difluoro-1H-quinazoline-2,4-dione; and

3-Benzyloxy-6,7-difluoro-1-cyclopropylmethyl-1H-quinazoline-2,4-dione.

30 15. A compound selected from:

1-Ethyl-6,7-difluoro-3-hydroxy-1H-quinazoline-2,4-dione; and

6,7-Difluoro-3-hydroxy-1-methyl-1H-quinazoline-2,4-dione.

16. A compound selected from:

3-Benzyloxy-1-ethyl-6-fluoro-7-pyrrolidinyl-1H-quinazoline-2,4-dione;

5 3-Benzyloxy-1-ethyl-6-fluoro-7-piperazinyl-1H-quinazoline-2,4-dione;

3-Benzyloxy-1-ethyl-6-fluoro-7-morpholino-1H-quinazoline-2,4-dione;

10 3-Benzyloxy-1-ethyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-1H-quinazoline-2,4-dione;

3-Benzyloxy-6-fluoro-7-pyrrolidinyl-1H-quinazoline-2,4-dione;

1-(3-Benzyloxy-6-fluoro-1H-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid, tert-butyl ester;

15 1-(4-Hydroxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(4-Fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(4-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

20 1-(4-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

1-(4-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

25 1-(4-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

1-(4-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

1-(3-Chloro-4-fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

30 1-(3-Chloro-4-fluoro-phenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

-128-

1-(3-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(3-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

5 1-(3-Methoxyphenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

1-(2-Fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

10 1-(2-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

1-(3-Fluorophenyl)-6-fluoro-3-benzyloxy-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(3-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(4-methylpiperazin-1-yl)-1H-quinazoline-2,4-dione;

15 1-(3-Fluorophenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

1-(2,4,5-Trifluorophenyl)-6-fluoro-3-benzyloxy-7-(3-t-butoxycarbonylamino-pyrrolidin-1-yl)-1H-quinazoline-2,4-dione;

20 3-Benzyloxy-1-cyclopropyl-6-fluoro-7-pyrrolidinyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzyloxy-1-cyclopropyl-6-fluoro-7-(4-methylpiperazinyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzyloxy-1-ethyl-6-fluoro-7-pyrrolidinyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

25 3-Benzyloxy-1-ethyl-6-fluoro-7-(4-methylpiperazinyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzyloxy-1-ethyl-6-fluoro-7-[3-(N-tert-butoxycarbonylamino)pyrrolidin-1-yl]-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

30 1-Benzyl-3-benzyloxy-6-fluoro-7-pyrrolidinyl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzyloxy-1-cyclopropyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

-129-

[1-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester;

5 [1-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl-methyl]-carbamic acid tert-butyl ester;

[1-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-azetidin-3-yl]-carbamic acid tert-butyl ester;

10 (1 α ,5 α ,6 α)[3-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester;

[4aR-(4a α ,7a α)]6-(3-Benzoyloxy-1-cyclopropyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-octahydro-pyrrolo[3,4-b]pyridine-15 1-carboxylic acid tert-butyl ester;

5-Benzoyloxy-8-fluoro-9-pyrrolidin-1-yl-2,3-dihydro-1-thia-3 α ,5-diaza-phenalene-4,6-dione;

[1-(5-Benzoyloxy-8-fluoro-4,6-dioxo-2,3,5,6-tetrahydro-4H-1-thia-3 α ,5-diaza-phenalen-9-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester;

20 (1 α ,5 α ,6 α)[3-(5-Benzoyloxy-8-fluoro-4,6-dioxo-2,3,5,6-tetrahydro-4H-1-thia-3 α ,5-diaza-phenalen-9-yl)-3-aza-bicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester;

3-Allyloxy-1-benzyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

25 1-(3-Allyloxy-1-benzyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester;

3-Benzoyloxy-1-(2-fluoroethyl)-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

30 1-(3-Benzoyloxy-1-(2-fluoroethyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester;

-130-

3-Benzoyloxy-1-(2-fluoroethyl)-6-fluoro-7-(ethyl-pyrrolidin-3-ylmethyl-amine-1-yl)-1H-quinazoline-2,4-dione;

3-Benzoyloxy-1-(2,4-difluorophenyl)-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

5 1-(3-Benzoyloxy-1-(2,4-difluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester;

3-Benzoyloxy-6-fluoro-1-(4-fluorophenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

10 3-Benzoyloxy-1-butyl-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzoyloxy-6-fluoro-7-pyrrolidin-1-yl-1-(4-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

15 3-Benzoyloxy-1-(2,4-difluorophenyl)-6-fluoro-7-pyrrolidin-1-yl-1H-pyrido[2

3-Benzoyloxy-6-fluoro-1-(4-methylphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzoyloxy-6-fluoro-7-pyrrolidin-1-yl-1-(3-trifluoromethylphenyl)-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

20 3-Benzoyloxy-6-fluoro-1-(2-fluorophenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

3-Benzoyloxy-6-fluoro-1-(4-methoxyphenyl)-7-pyrrolidin-1-yl-1H-pyrido[2,3-d]pyrimidine-2,4-dione;

25 3-Benzoyloxy-1-cyclopropylmethyl-6-fluoro-7-pyrrolidin-1-yl-1H-quinazoline-2,4-dione;

1-(3-Benzoyloxy-1-cyclopropylmethyl-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-quinazolin-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester;

30 1-(3-Benzoyloxy-1-(4-fluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-pyrido[2,3-d]pyrimidine-7-yl)-pyrrolidin-3-yl]-carbamic acid tert-butyl ester; and

-131-

(1 α ,5 α ,6 α)[3-(3-Benzoyloxy-1-(4-fluorophenyl)-6-fluoro-2,4-dioxo-1,2,3,4-tetrahydro-pyrido[2,3-d]pyrimidine-7-yl)-3-azabicyclo[3.1.0]hex-6-yl]-carbamic acid tert-butyl ester.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/19877

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D239/96 C07D403/04 C07D471/06 C07D471/04 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 108, no. 23, 1988 Columbus, Ohio, US; abstract no. 204459q, GHONEIM, K. ET AL.: "novel 2-substituted aminonicotinhydroxamic acids." page 656; column 2; XP002090463 see abstract & EGYPT. J. PHARM. SCI., vol. 28, no. 1-4, 1987, pages 9-16, -& DATABASE CHEMICAL ABSTRACTS XP002090465 AN 108-204459, see RN 114501-32-5 and RN 114501-30-3 --- -/--	1

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 February 1999

Date of mailing of the international search report

08/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

international Application No

PCT/US 98/19877

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 126, no. 8, 1997 Columbus, Ohio, US; abstract no. 98827t, CIANCI, C. ET AL.: "identification of n-hydroxamic acid" page 15; column 2; XP002090464 see abstract -& DATABASE CHEMICAL ABSTRACTS XP002090466 AN 126-098827, see RN185963-61-5 see abstract & ANTIVIRAL CHEM.CHEMOTHER., vol. 7, no. 6, 1996, pages 353-360, USA ---	1
X	J.L. ROMINE ET AL.: "SYNTHESIS OF 3-HYDROXYPYRIMIDINE-2,4-DIONES." SYNTHESIS., vol. 8, 1994, pages 846-850, XP002090460 STUTT GART DE see page 846 - page 850 ---	1
X	KOU-YI TSERNG, L.BAUER.: "NOVEL LOSSEN REARRANGEMENTS OF 3-BENZENESULFONYLOXY(1H-AND 1-METHYL)-2,4-QUINAZOLINDIONES" JOURNAL OF ORGANIC CHEMISTRY., vol. 38, no. 20, 1973, pages 3498-3502, XP002090461 EASTON US see page 3498 - page 3500 ---	1
X	KOU-YI TSERNG L.BAUER: "3-HYDROXYPYRIDOPYRIMIDINE-2,4(1H,3H)DIONE S." JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 9, no. 6, 1972, pages 1433-1435, XP002090462 PROVO US see page 1433 - page 1434 ---	1
A	EP 0 316 630 A (WARNER-LAMBERT) 24 May 1998 see claims; examples 44,45 -----	1,12

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/19877

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 13
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Information on patent family members

PCT/US 98/19877

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)